2024-03-31-accounts

REGISTERED CHARITY NUMBER: 1159115 Report of the 'fru$tees and inancial StAtements for the Year Ended 31 ivlareh 2024 for British PaediAlric Tr4eurology Association

Brltlsh Paedlatrlc Neurology Assoclatlon Contents of the Flnancial Ststements for the Year Ended 31 March 2024 Page Report of the Trustees I to 29 Report of the Independen¢ Audltor 30 10 32 Statement of Financial Actlvities 33 to 34 Balance Sheet 35 Cash Flow Statement 36 Notes to the CAsh Flow Slatement 37 Notes to the Financlal Statements 38 to 60

British Paediatric Neurology Association Report ol the Trustees Cor the Year Ended 31 March 2024 The Iruslees present Iheir report with the financial statements of the charity for the year ended 31 March 2024. The trustees have adoplc(I thc provisions of Acc'ounting and Rcporting by Charities= Statement of Recommended Practice applicable io charities preparing their accounts in accordance with the Financial Reporting Stsndard applicable in the UK and Repiiblic of Iicland (FRS 102) (cffcclivc l January 2019). Pre5ident'5 Report It has bcen a pleasuic lo take over tlie Presidcncy of the BPNA with the organisation in such great shape. I would like to 6(ari by thanking Alasdair Paikcr. immediutc Past President, for his strong leadership navigating Lhe BPNA out of the pandemic and strengthening our work acro.ss all our charitable activities. The BPNA h&s now reached Ihe status of a mediiim charity on aCCOUDI of our financial iuTnoYcr and with growing outputs across all areas of the organisation. Particular highlights in 2023-24- UK Education continues to grow and refresh. PET4ward h&8 been develoFd as a new Course and there have been uwiales io existing courses lo ensure these remain slate of the arl. There was a return of some courses lo F￿e io Face whilsi coniinuing Some in the virtual environmenl in order lo meet the needs of the parlicipanls. Iniernational Education 15 moving forwards with establishing courses in new countries incliiding a launch in Zambia for ZambAalZAmbabwe and continuing to work with Ilie International League Against Epilepsy (ILAE) to facilitate the roll-out of PEf worldwide. The International team were successful in attaining a competitive Tropi¢al Health and Education Trust (THET) grant 10 Support the BPNA to work with partners in Ghana and Kenya to roll PETI out in rural areas. Patient and Public Involvement collalx)ralion has broadened beyond input lo conference and includes feedback to infom short course development, meeting with patient groups and linking in with SExcial Interest Groups A very successful 50th annual conference in Bristol from scientific, networking and social perspectives with 726 delegates from 47 countries A growing membership with over 700 members Conunuing io attract trainees to Paediatric Neurology and overseeing the training of Ihe next generation of Paediatric Neurologists and supporting the training of other medical professionals Appoinlment of Philip L£vine as Dittcior and expansion of the secretariat to deliver the increasing activities of the organisation Over Ihc ncxt ycar wc plan to consolidate and further develop. The 8lrategy day in Septemkr 2024 will be opporlunily lo onsidcr the vision of the BPNA and how we can achieve ihi% t()geiher. would really like 10 thank thc Sccrclariat, Exccutive, Council, all BPNA members and volunteers for their continuing ccjmmilmenl and cnihusiabm for thc activilics of thc organisation. The day job. in Ihc NHS is IKcoming increasingly challenging and despite this you find time to work together to deliver our haritable aim of promoting the health and well-being of children with neurological disorders. Dr Ailsa McLellan BPNA President (2024 - 2027) Page I

Bri¢tsh Paediatric Neurology Association Report of the Trustees for the Year Ended 31 Mareh 2024 OBJEcfivES AND ACTIVITIES Objectlves and aims The British Paediatric Neurology Association (BPNA) is a charitable incorporated organisalion registered wilh ihe Charity Commission for England and Wales on 6 November 2014 with the charity number 1159115. The objectives are co proniote the health and well-being of children with neurological disorders through: The training and edu¢ation of professionals working in the field of paediatric neurosciences- The promotion of ￿Search into the causes, effects and trearmenis of neurological disorders affecltng children and young people,. The improvement of knowledge of professionals, the publi¢ and patients and their families Ihrough scientific and educational meelings., and The provision of professional support to members io facilitaie the delivery of the above objectives and work with t]ealth servA¢e planners and providers lo achieve this aim. Main activities undertaken in relation to the purpose Please see full details of each activity provided in 'Achievement and performance,. Training the next generation of paediatric neurologisis in the UK. Educating professiona18 in the UK and internationally in ihe diagnosis and manageTnenl of.. Epilepsy, through provision of Paediatric Epilepsy Training (PET) and Expert to Expert- Epilepsy courses,. Movement disorders, through provision of Expert to Expert.. Movement Disorders; Headaches, through provision of Children's Headache Training (CHaT) courses., Neonatal neurology, through provision of INeoNATE) ¢ourses Abnormal muscle lone, through provision of the Approaching Children's Tone (ACT) COLirses Acute neurological disorders through ihe newly developed course Acute Children with any type of neiirological condition through its comprehensive online distance learning course. Improvemenl of knowledge of professionals, the public and paiients through the annual scientific meeting held in JanLiary. Promotion of research through.. British Paediatric Neurology Surveillance Unli (BPNSU)., and Paediatric Neurology Research Fellowship. Provision of professional support through: Mentoring; Team support., Special interest groups Page 2

British Paediatric Neurology Assoclatlon Report of the Trnstees for the Year Ended 31 March 2024 Public benefit The Iruslees have had regard lo the Charity Commission's guidance on public benefit in considering activilies during 2023-24. They sought lo meet the public benefit of promoting the health and wellbeing of children with neurological disorders in the UK and globally through the initiative5 and projecis listed in the section 'Main activities undertaken in relation to the purpose,. OBJECTIVKS AND ACTIVITIES GrAntm8king During 2023-24, th¢ Charity provided £41,302 funding the third year for the second joint BPNA A¢lion Medical Research {AMR) fellowship and £41,667 funding the second year for the third joint BPNA Aclion Medical Research fellowship. Volunteers BPNA faculty in the UK and overseas directly contributed to the development and delivery of courses and distance learning. They also contribute their expertise in the other areas of the BPNA including Professional Support and Research as Chair, Council and Committee members. YoLi can define all these people as volunteers who give their time to the BPNA as a charity. Their contribution is significant to the ongoing activates of the BPNA and the trustees wholeheartedly appreciate this commitment and thank them. Fundralslng BPNA raises funds through applying for grants from organisaiions Ihal have the same interests. The charity has used its own staff for fundraising and not any external fundraiser.%. Tlie cliarily is not a member of any voluntary scheme for regulating fundraising. All fundraising activitie5 are monilored by the Direclor and the charity has not received any complaints regarding its fundraising activities. The charity doesn't come into contact with vulnerable people as it is not involved with street or door to door fundraising. ACHIEVEMENT AND PERFORMANCE Charitable •etivities l. Tralning l. l. P<iediatric Neurolo Siib-s ecialt Traiiiiiio The BPNA Continues lo have responsibility for training paedialric neurologists in the UK with BPNA members serving on the Royal College of Paediatrics and Child Health (RCPCH) College Specialist Advisory Committee ICSAC) for neurology.The committee is Chaired by the BPNA President and include8 the BPNA National Training Advisor. The GMC and RCPCH Shape of Training (SOT) plans on paediairi¢ neurology training are now finalised and will be comTnencing in August 2023. Il has been agreed that neurology GRID trainees will still have up lo 3.5 years lo meet learning d)jeclives. .2. New curriculum Trainees and their ediicational supervisors are becoming more familiar with the Level 3 neurology 'Progress' syllabus, which was launched in August 2018. The BPNA Training Guide to Neurology, published on the RCPCH website, continues io provide more specific and structured information on how to achieve the learning objectives and capabilities for Level 3 neurology (GRLD) training. The CSAC has developed an Annual Progression Form which incorporates the curriculum and trainees have provided positive feedback regarding this. .3.A oinlineiii ()f new rid Ir4Trinee. For the 2023 paedialric neurology GRID Iraining programme, there were 9 GRID training schemes available. Over thirty applications were received, and 19 trainee5 were shortlisted for interview. 16 candidates were deemed appointable, and 9 trainees accepted a GRID position. Overall, this is a hLige increase in number of trainees applying to the GRID scheme in comparison lo previous years. Page 3

British Paediatri¢ Neurology Association Report of the Trustees lor the Year Ended 31 March 202A There has also been a change in number of attempts ai GRID applications. Unlimiied aitempts are now being allowed. provided the trainee has had equivalenl training up to the siage of entry, counting a m&ximum of 12 months of equivalettt experience. In 2020. the BPNA established a Recruitmenl Working Group lo develop strategieb to encourage junior do¢tors lo consider a career in paediatrtc iieurology. Variou5 initiatives have been implemented to aid prospective irainees in making successful applications inclLiding a careers page on ihe BPNA web8i¢e with webinars on applica(ions and interviews and genei'al iopics in paedtairic neurology. Feedback on Ihese sessions have been very posiiive overall. 1.4. As'%es%iiienl und SLI orl for Existin Trainee All traii)ees receive an annual viriual CSAC progression interview. In the past year, mosi trainees have been making good progress. There are challenges for some irainees to access outpatient aciivities in specific centres and the Neurology CSAC have been supporting the local ieams to address ihis. A shortage of consultants in substantive posts has impacied on their ability lo irain in some cenires. 1.5.S ecial Inicrcsl niocllilc in E ill The Neurology CSAC have rewrillen ihc Special Inieresl (SPIN) Epilepsy curriculum in 2022 and this has now been endorsed and signed off by the RCPCH. The BPNA are l(K)king al more ways to support Trainees taking on SPIN Epilepsy. 1.6. Ai4eE¥ffleIii of'Noii-Grid' Trainin Doctors who have noi completed the UK paediatric neurology GRID training prograwnme. bul who can show they have knowledge. skills and experience equivalenl to the approved curriculum. can request entry on the GMC specialty register via the ceri1fica￿ of Eligibility for Specialist Registration (CESRI route, if part of their (raining was done overseas. The Neurology CSAC has a role in evaluaiing CESR applieations. If the GMC approve the initial appliealion. the Neurology CSAC will review the neurology component of their training and determine wheiher il is equivalent to that of a UK GRID Irainee. Typically, only training in ihe 5 years prior to the CESR applicaiion can be?considered and if successful, Ihe applicant will eniered onto the GMC speclalist register. If a irainee cannot apply for CESR accredilaiion, they can apply lo the CSAC to delermine whether iheir training has been 'eqiiivalent' to Ihat of a UK GRtD trainee. Given the difficulty in assessing training via the generic NHS shortlisling programme and lor dui'ing a brief inierview, this is a more robust method of supporiing the RCPCH represeniative on Advisory Appoinlmenls Commiltees (AAC) in ensuring that candidates applying for a consiiltant paediatric neurology post are suilably irained to fulfil the role. Of note. a 'Leller of Equivalence, does not allow entry on the specialist register. 1.7. A rnvul ol New Posi% Job plans for all new consulianl paediatric neurologisl posis submitied by hospitals lo the RCPCH for approval are reviewed by Ihe Neurology CSAC. The Generic Guide lo Consultant Paediairic Neurologist Job Planning, published by the BPNA in 2018, has been invaluable in supporting centres in ensuring their jobs are sustainable and will allow new consulianis lo meet the needs of children and young people with neurological disorders. Final approval for consultant paediatric neurology jobs is given by the RCPCH Training Serviee.g team. 2. Education 210 BPNA taculty in the UK and overseas directly contribuied to the developmeni and delivery of coiirses during 2023-24. This demonstrates the strong motivation and engagement of faculty, and ihe trLisiees wholeheai'iedly appreciate this commitment to teaching and Iraining. The BPNA short courses run either in a virtual or face-lo-fa¢e setting. wilh the majority taking place online. Sonie courses are hoping io return back to a face-lo-face setting or a mixlure of running the courses both online and face-lo-face and some remaining eniirely online. Page 4

Brltish Paediatric Neurology Assoclatlon Repor¢ of the Trustees for the Year Ended 31 March 2024 l. Pdcdiatric Epilcpsy Triiiniii PET PET Icaches safe slandard epilepsy praclice to clinicians, using conscnsus-based. peer-reviewed. standardised materials linked lo inlernalionally rcco¥ni5cd clinical guidelines. Introduced to improve sthndards of care ol childrcn with cpilcpsy, we aim lo d¢liv¢r courscb thioughout the UK every year. AII PETI, PET2 and PET3 courses took place in a virtual .qetting again in ycar 2023-24 with PET week {PET123 in one wcek) running in a face-to-face seLling. Virlual ¢ourscs have tEsulted in a reduced number of PET courses compared io when they ran face-to-face pre-pandcmiL'. PETI (l-day) 6 courses (2019-20=10) PE12 (2-d&ys) 3 courscs (2019-20J- ) - PET3 (2-days) 2 courses {2019-204) Since 2005 to 31 March 2024, 12,840 UK clinicians have allended a PET course (2023-24=697. 2022-23=726- 2021-2L702). contributing to improving the standards of diagnosis and management of children with epilepsy in the UK. Feedback from virtual ¢our5es has been excellelll. The PETI course materials were updated by a team of internalional clinicians in March 2023. The updated PETI materials were used in the UK froTll May 2023. The PET23 course materials were updatrd by a team of international clinicians in November 2023. The updated PET23 materials will be used in (he UK from June 2024. A Consulianl Paediatrician with a special interesl in epilepsy is employed for 4-hours per week to manage course development. Q 2. Cliildrcn's 14eaduche Traiiiiii CHa'r This one-day course is delivered by paediatric neurologists and paediatricians with expertise in the management of headaclie. The purpose of CHaT is to improve knowledge and skills amongsl health professionals who care for children and young people with headache. CHaT was adapted for virtual delivery during the coronavirus pandemic. In 2023-24, four virtual CHaT courses were held. During 2023-24 CHaT welcomed internalional attendees from Austria, Belgium, Greece, malt￿ New Zealand, Norway, Sudan, Turkey and United Arab Emirates. CHaT course materials were updated by a UK fram in 2018. Since 2012, 1.661 clinicians have attended CHaT {2023-2AL163. 2022-23=198. 2021-22-138. 2020-21-117). 2.3. NLonalal Nclirolo As%e%smenl llnd Ti'eatnieni Bdlicaiioii NeoNAI'E Infanl8 born at Icrm vr prcmalurely are susceptible to neurological condilions whose long-lenn OLilcomc6 Can bc much improved by cffcclivc carly rccognition and intervention. "I'his prnclical 2-day cour5c was inlroduccd in 2014 to provide training for paedidiriLian6 dnd nconatologibts caring for newborn infants in dislricl general ho8pilal8. It 18 delivered by paediatric neurolo¥isls and nconatologisL5, lind this unique course gives a complemenlary per8￿Ctive on a wide range ol ncurological conditions. NeoNATB course nialerials were updaied by a UK team in 2018. The NeoNATE course was not adaptcd for virtual dclivery and no courses run during the pandemic, belween 2020 - 2022. In 2023-24, NeDNAI'E ran two courscs hcld in a facc-lo-face setting. Since 2014. 708 clinicians have attended NeoNATE (2023-24=72. 2022-23=80", 2021-224); 2020-21=0). During 2023-24 NeoNATE welcomed international attendees from RomaniL Singapore and Switzerland. Page 5

British Paediatric Neurology Association Report of the Trustees for the Year Ended 31 March 2024 2.4. E,x erl to bx erl InleTnational keynote speakers and UK faculiy deliver an annual 2-day course, providing coniinuing professional development for Consuliani Paediatric Neurologists from the UK and globally. On alternate years, the course focuses on Epilepsy or Movement Disorders. In 2022-23. 39 people allended Expert to Expert: Epilepsy, wilh international attendees from Malaysia I l ), Netherlands12} and Norway (l }. The next course will rake place in 2024-25. CliildF¢n's Tone ACT Children with abnormal muscle lone deserve prompl recognilioii and timely access lo appropriate invesligalion and treatment, parlicularly with the availabilily of new therapies foi. neLiromuscular conditions and cerebral palsy. In view of Lhis. the BPNA developed a short course on tone managemeni in children called 'Approa¢hing Children's Tone, (ACT). The Acr ¢ours¢ was developed for virlual delivery. Since the running of the first course in 2020-21. 350 clinicians have a[￿llded ACT (2023-24=128; 2022-23=94. 2021-22=92; 2020-21=36). 2.6 AcLlte Paediairic NLurolo Il is estimated that aboui a third of all paediatric emergencies are neurological. We are aware of Ihe volume of children attending emergency departments with neiirological preseniaiions, and of ihe anxiety this can create for the re¢eiving paediatricians and trainees, who often feel inadequately trained in acuie paedialric neurology. In view of this. the BPNA in collaboration with the Association of Paedialric Emergency Medicine developed a l-day course called Acute Paediairic Neurology. The Acute course was developed for virlual delivery. Sin¢e Ihe running of the firs( course in 2021-22. 199 clinicians have aiiended Acute (2023-24-73; 2022-23=91: 2021-22=35). 2.7 Mnveiiieni Disorder% EIlLICiilion MOVED Unusual movements in children Can sometimes be difficult lo describe and ¢ategorise. MOVED is a 2-day course which aims lo cover a broad spectrum of movement disorders thal are seen in children and will place emphasis on description, diagnosis and initial management of these conditions. Thi5 newly developed course has been adapted from the previous Expert to Expert: Movement Disorders course. The MOVED course was developed foi both vlriual and face-lo-face delivery. The first course ran in 2023-24 with 35 linicians aiiending. 2.8. 1)ISl<lliCC LLariJin In¢roduction Distance Learning (DL) provides sysrematic and comprehensive learningi delivered online for trainee paediatric neurologists, paedialricians and established specialists. The course covers the whole of paediatric neurology and palli¢ipants may enrol for one or more unils. DL fees are differentiated by couniry according lo (he World Bank eeonomic classificalion lo widen access lo doctors worldwide, in line with BPNA charitable aims. During 2023-24, 181 doctors eni'olled from 35 countries. in PaLdiali'ic Neurolo Tr Distance L£arning complements BPNA short courses. providing depth and exlending the knowledge gained at a one- and (wo-day courses. Woi'king with respective short-course development teams. explicit links are being provided in DL units to reinforce ihe learning provided in the related short-courses. Thus, we en¢ourage'. PET attendees to study Unit 6 Epilepsy NeoNATE attendees lo sludy Unil 2 Neonalal Neurology CHaT allendee5 to study Unil 12 Headache ACT aiiendees to study Unit 5 Neuromuscular and Unit 4 Ceniral Motor Disorders A¢uie Paediatric Neurology attendees lo study Unil 13 Acute Paedialric Neurology Page 6

British PaediatTie Neurology Association Report of the Truslees for the Year Ended 31 MArch 2024 Updating content Dislance Learning is hosted on the Moodle plarforn). A Consultant Pucdialri¢ Neurologist is employed for 4-hours per week to direct and oversee the constanl revision and rewriting pmcess. The Dislance Lvatning Sl¢cring Group. consisting of onel two experts per unit, meets twice per year. Distance Learning development hab u reserve lo fuTJd dcvclopmenl for upjaling Units and paying for the external Moodle plailoim piovidcr cfilus Lcatning)2021-2024. During 2023-24, Unli 8 Inflammation and infection of the CNS major U￿tale was complctcd. Enrolments During 2023-24, there have been 503 cniolments on distance learning units. by 181 people from 35 counlries. The highcsl proportion of Lhese cnrolments are from the UK, 50.79% (256 of 503). Of Éhose 503 enrolments 135 of those were as part of a bundle package. Acknowledgements We are indebied to the Consultant Paediatric Neurologist volunteer liiiors in the UK and globally, who give their time to lulor students ihrough the course. We give enorn)oiis thanks to &11 those Consultants across the subspecialties who ontribute to the course contenl development, including preparing and givffing BPNA webinars. 2.9. Webinar Leciure Series Covid-19 led io a ¢l)ang¢ in trainee'5 working patterns ihat resulted in them having restricied access to appropriate leaching. In response, the BPNA Presideni launched a free weekly Webinar Lecture Series. BPNA webinar leciure serie5 wa5 launched as a free weekly viriual learning resource for child health professionals, in parti¢ul&i' those working in paediats'ic neurosciences worldwide. The first lecture was given on 14 May 2020 and lectures have been delivered weekly up until September 2022, with a couple of short breaks for holidays. Since October 2022 the webinar lectures have been delivered on a monihly basis with focus on special interest condition topics that the BPNA Special Interest Group Chairs suggests. This would not have been possible withoiit the generosity of BPNA members giving their lime. We are graleful (o Ihem all for preparing and delivering such excellent IcLlures on wide range of topics and for remaining until all the question5 have been answered. Recordings of IcL'lures a￿ available in the BPNA members, area and are also provided on the distance learning platform for enrolled students to access. During 2023-24, the webinar Icctiire series has been attended by boih IrainLCS and consulianis worldwide. 776 doctors and allied health prufcs.4iUll¢i16 from 64 countries have atlended 9 BPNA monthly wcbinar Iccturcs. 11 ha5 been acknowledged that the webinars are a grLUt promotion to thc BPNA'S brand and charitable objectives and ihal Ihcy should carry on. 2.10. Inlernalional ShDrt-Courses In 2022. the World 14ealth As5cmbly unanimously ratified ihe WHO'S In(er8ectoral Gl(Jbal Action Plan OD epilcpsy and other neurological disorders. PET contributes to strengthening Ihe health workforce. one OF the Plan's key levers for change. Ag&in.st this backdrop, we were pleased io see internauon&l PET atlendco numbers rising to pre-pandemic levels in 2023-24, as well as the launch of PETI in Zambia and Zimbabwe. We are grateful to the ILAE and Ihe BAND Foundation for their support of the launch. We were also pleased to secure a grani from ihe Tropical Health and Education Trusl (THET), awarded on behalf of the Department of Health and Social Care. The grant was awarded under THET'S Global Health Workforce Programme and 15 supporting the BPNA to work with partners in Ghana and Kenya lo roll PETI out in rural areas. Page 7

Britlsh Paediatric Neurology Association Report of the Trnstees for the Year Ended 31 March 2024 Thig was the second year of BPNA'S new four-year partnership (2022-2026) with the International League Against Epilepsy (ILAE), whivh was fonned to lacilitalc the roll-oui of PET worldwide. The initial memoranduTll of underqlanding has a value of $278,844 ovcr that time. Trustccs are cogniNdnt vl. thc need to ensiire international launch and delivery of courses is SLlStainable and that all Course.￿ meet our dcftned qualily standurds. The BPNA and ILAF. sharc a commitmenl lo iJnproving care foi children wilh epilcp5y. In 2005, the BPNA developed Pl￿[IatrIC Epilepsy 'fraining (PET) courses lo train hcalthcare workers to bcttei diagnose and trcat children wilh 5cizures. PETI is now atlendcd by almost every pacdiatrician in Ihe UK und the course.q have also bccn launched ovcr5cas, 8eiiing a gold siandard tor epilepqy cai'c around the world. Oulsidc of the UK. the programme currenily runs in.. Aiistralia, Brazil. Colombia, Ghana, Lndia, Kcnya. New Z¢aland, Singapore. South Alrica, Tanzania. Uganda, Zambia and Zimbabwe. PET aligns with the ILAE'S Educ<ltion Council'5 aim to leach compelency in the diagnosis and clinical management of epilepsy, wirh a focus on non-specialists i.e. paedialricTans. It forms parl of the porEfolio of educationdl aclivilies thai the ILAE aims to develop. It also supports Goal 2 of the ILAE'5 Strategy 2030- Support health professionals worldwide to enhance their knowledge and skills in the prevention. diagnosis, Ireatment and care of epilepsy. The BPNA and the ILAE first signed a partnership agreement in 2018, committing to build on the success of the Paedialric Epilepsy Training courses developed by (he BPNA. The ILAE hab ag￿ed to cover 40% of staff costs in ihe BPNA'S International Education team (3 staff members) from April 2022 to March 2026. The total number of attendees outside the UK and Republic of Ireland is 6,825 (PETI = 5,327. PET2 = 624; PET3 = 283; iPET= 274; Trained as faculiy = 285). 2.10. l. Middll E¢i%l & Nordi Al riLu Middle East.. No courses were delivered in 2023-24. PF.Tl altendance sinc¥ 2014.. 171 (2023-24= O- 2022-23 = 0. 2021-22 = 15). PET2 atlendance since 2014.. 133 (2023-24= 0; 2022-23 - 0. 2021-22 = 14). North Africa.. SuLlan= No Sudanesc altendeeq joincd at PET or PF.T2 course in 2022-23. Due to the gco-political situaiion, courses in Suddll have been paused. PETI allcndance since 2014= 297 (2023-24 = 0. 2022-23 - 0. 2021-22- 8}. PETr altcndance since 2014.- 109 (2023-24 -0. 2022-23 - 0; 2U21-22 = 0). 2.1 U.? ,Siib Sa11aruii Al'i'ic Angola. PETI Aiiendance since 2019 = 50. (2023-24= 0,. 2022-23 - 16- 2021-22 = 0). Ghana in partnership with the Paediatric Socieiy of Ghana. During 2023-2024, one course was held. with 47 attendees. Since 2018, the total number of PETI attendees is 311 (2023-24= 47- 2022-23 = 33; 2021-22= 11). Kenya in partnership with the Kenya Paediatric Association. Durtng 2023-24, four PETI ¢our,ses were held wilh 184 atiendees and one PET2 course was held with 20 aiiendees. PETI atÉendan¢e since 2017 49412023-24= 184. 2022-23= 48: 2021-22= 111. PET2 attendance since 2020= 78 (2023-24= 20. 2022-23 = 39; 2021-22 - 16). Page 8

British Paedlatrlc Neurology Associgtion Report of the Trustees for the Year Ended 31 March 2024 Mozambique. PETI auendanee since 2021 = 24 (2023-24= 0; 2022-23- 16; 2021-22- 8). Souih Africa in partner.￿￿1p with the Pacdialric Neurology Developmeni Association of Southern Africa. Three courses wcrc delivered by South African faculty in 2023-24. A iolal of 99 delegates attended the col1r.￿es. PETI allendance sittcc 2015-16= 478 {2023-24- 99- 2022-2023 = O- 2021-22 - 55). Tanzania in partnership with the Paedialric Association of Tanzania. One course wag run in 2023-24, with 49 altcndccs. Sincc 2018, tlie total number of PET l allendees is 233 (2023-24= 49- 2022-23 - 41. 2021-22 = 0). Uganda in partnership with the Uganda Paediatric Association. During 2023-24, one PETI course was delivered to 34 delegales. Since 2018, the total numbei. of PETI attendees is 170 {2023-24 = 34. 2022-23 = 0; 2021-22 - 9). Zambia in partnership with the Zambian Paediatric Association. PET was laun¢h¢d in Lusaka in May 2023, and faculty from Zambia And Zimbabwe were trained. Since 2023, the loial numb¢r of PETI attendees = 62.12023-24= 62). Zimbabwe in partnership with the Paediatric A5socialion of Zimbabwe. Faculty from Zirnbabwe weie trained at the pEr launch in Lusaka in May 2023. Since 2023, Ihe total number of PETI attendees = 48.12023-24 = 48) 2.10.3. Asia India in partnership with Raindrops Children's Foundation. PETI was launched in northern India in 2014 and southern India in 2016. In 2023-24, seven face-to-face courses were held. Total PETI attendees in India since 2014: 1.634 (2023-24 336. 2022-23 45; 2021-22 = 88). data not currently shared with the BPNA. This is an estimate based on the number of courses that were Tun and Ihe typical number of delegates attending a course in India17 courses with 48 people each). Myanmar- PET I was launched in Myanmar in 2014. Since then, 313 people have attended PETI {2023-24 = 0. 2022-23 = O- 2021_22 = 0). Courses in the country are on hold due io the cuttent political situation. Singapore in parlnership with KK Women's and Children's Hth%pital. Onc PETI course was held with 21 altendees. Sin¢e 2021. thc total number of PETI atlendees is 28 {2023-24= 21- 2022-23 = 0; 2021-22- 0). 2.10.4. Ccntral & Souih America BraLil in pdrlncr%hip with Liga Brasileira de Epilcpsid. During 2023-24, four PETI courscs wcre held with a tolal of 75 dclcgates. PET2 launched in Brazil in 2023-24. One PET2 coursc was hcld with 24 delegates. PETI attendance since 2018 285 (2023-24 = 74; 2022-23 - 32,. 2021-22 - 40). PET2 attendance since 2023 = 24 (2023-24= 24). Colombia in partnership with Aso¢ia¢ion Colombiana de Neurologia Infantil and Universidad de Anlioquia. Two PETI courses were held with 54 attendees. PETI attendance since 2021 = 132 {2023-24 - 54., 2022-23 63. 2021-22= 15). 2.10.5. Auslralasia Australia in partnership with the Australia and New Zealand Child Neurology Society IANZCNS) During 2023-24, two PETI courses were held with a tolal of 60 delegales and two PET2 courses were held with a total of 47 delegates. PETI attendance since 2021 = 16712023-24= 60; 2022-23 = 94- 2021-22 = 13). PET2 attendance since 2022 = 7112023-24 - 47. 2022-23 = 24). Page 9

British Paedi4tric Neurology Asgoeiation Report of the Trustees for the Year Ended 31 March 2024 New Zealand in partnership with the New Zealand League Against Epilepsy and the Starship Foundation. During 2023-24, two PETI courses were held, one PET2 course was held and one PET3 course was held. PETI attendance since 2017.. 429 (2023-24= 41. 2022-23 = 83. 2021-22 = 25). PET2 allendance since 2017.. 233 (2023-24 = 31; 2022-23 = 32,. 2021-22 - 31). PET3 attendance since 2018.. 212 (2023-24= 32. 2022-23 = 54; 2021-22 = 0). 2.1 l. Evaluation of edu¢alional activities BPNA'S edu¢alional activities are designed io promote the health and well-being of children with neurological disorders. We are commilled to evaluating them to ensure that they do 50 and lo adapting them on an ongoing basis. After coniplelion of any of our educational aclivilies, learners are required ro complete a feedback forni to assess their level of satisfaction with the course. At PETI courses, learners also coniplete a pre- and post-cour5e quiz to assess knowledge-gain. and, six months later. a follow up survey to establish Ihe changes that they have made io their clinical practice. These data have been analysed by a group of researchers froni the BPNA and the University of Dundee and, in 2024, they were published in a paper entitled Reducing epilepsy diagnostic and treatment gaps.. Siandardized paediatric epilepsy training courses for health care professionals in the journal Developmental Medicitte and Child Neurology. We found that 98% of PETI delegates change their personal clinical practice after allending the course and 64% change their clinical service. 68% iniiiate or improve epilepsy teaching at their hospital. We are working with the University of Manchesler to furEher refine our evaluation methods for the PETI course by using a clinical behavioural-change methodology to furiher undersvdnd the impact of the course. It is hoped Ihat Ihese refjned evaluation tools can be adapted and applied to other BPNA short courses. Annual Scientific Conference Oversight of the scientific content of the annual meeting, including absiracl scoring and awarding of the MacKeiih Prize. rests with the Research Committee. The 50th annual scientific meeting was hosted by Bristol and held as a hybrid eveni in January 2024. There were 726 delegates from 47 COLintries. Technology facilitated high delegare numbers {2023 Edinburgh-816; 2022=941. 2021-1,134., 2020 BelfasiJ27) and geographic access. Opporiunities to learn were provided by 20 oral presentations and 217 posiers {s¢le¢led from 250 abstracts submitted); 7 keynote lectures. 4 clinical practice sessions,. and 6 sponsored symposiums. Page 10

Brltlsh Paediatric Neurology Association Report of the Trustees for the Year Ended 31 March 2024 2024 Prizes were awarded to.. Dr Dora Steel (Ev¢lina Children's Hospital, London) The Ronnie MacKeiih Prize. Awarded to the person who has made the most significant contribution to paediatric neurology as judged by published work and who is <40 year5 old or within 5-years of obtaining CCT. Dr Robert Spaull (Great Ormond Street Institiile for Child Health) Best oral pitsenlation by a trair]ee. Dr Susan Harvey & Dr Abigail Lazenbury (Great Omiond StreeL Hospital) & (Southamplon General Hospital) Best oral poster preseniaiion by a trainee. Dr Alison Skippen(Oxford) BPNA "BAFfA" Award for Fabulous Trainee Action.Awarded to the trainee who has besl contributed to service improvement which significantly impacled on iheir local andlor national practice or any other innovative conlribuiion. Miss Emily Gaskin (University of Sheffield) Best medical student presentation. Dr Samantha Chan (St George's Hospital, London) Development Medicine and Child NeLirology IDMCN) Besi Article by a BPNA Trainee Prize. 4. Pa(ieiil and Public Involvenicnl We had 22 paediatric neurology related cliarities attended the conference. 18 were able to take up a physical Stand and 4 others took up the opportunity lo have a virtual exhibition stand to engage with BPNA members and the other allendees. ppl To motivate delegates allending Lhe conference physically to visit and engage with our exhibitors this year, stamp cards were be provided. Delegates who collected 5 stamps from charity exhibiiors, had a chance lo win up to 4 £50 vouchers. The aim was lo open up on the opportunity for charities lo engage wilh atiendees at the conference and identify opportunities to improve the lives of children with neurological disorders. Each BPNA Conference venue has its challenges of where sland spaces can be located, and the BPNA aims for charities to have as much involvemenl as possible with their stand location. Feedbaek was received that stamp cards had a positive benefii bui ihere was room for improvemeni on engagement. The BPNA look forward lo hosting the charities again at the 2025 conference. A PANSPANDAS Working Group was sel up to discuss and liaise with PANS PANDAS UK in producing a PANS PANDAS Working Group Sialement with other colleges and groups. This was published in February 2023 and addressed the current variation across the UK in the management of paiienls presenting with Paedialric Acute-onset Neuropsychiatric Syndrome (PANS) and Paediatric Autoimmune Neuropsychialri¢ Disorders Associated with Streptococcal Infection5 (PANDAS). Since then plans for a PANS PANDAS Clinical Guidelines Development Group is lo be set up. The BPNA constantly looks to expand the PPI throughoiit the organisation as part of the charitable aims. Request have been made for PPI representation in the special interest groups, course development and as many other activities as possible. As well as trainees should be facilitated lo work with PPI and social media. We proposed increasing this area going forward. Pagell

British Paediatric Neurology Association Report of the Trustees for the Year Ended 31 March 2024 5. Research The BPNA research committee has a remit for oversighi of the annual s¢ientific meeting as outlined above. as well as for the speciality paediatric neurology session at Ihe annual Royal College of Paedialrics and Child Health meeting. The research committee also oversees the development of research within the organisalion (o the benefil of children wilh neurological disease. The BPNA Research Colnmittee is chaired by Dr Sam Amin. Members have a wide range of clinical and scientifjc expertise and come from a broad rallge of UK and Irish Paediatric Neurology Cenires. The research commiitee has been working to develop the agreed research strategy of the BPNA, focused on building research capacily within paediatric neurology and promoting research training within the paediatric neurology Irainee community. There is also BPNA Research ComTllittee represenlalion on the editorial board of Mac Keith Press for the Developmental Medicine and Child Neurology IDMCN) journal. Two Regearch Committee members and three other BPNA members. 5.1 British Paediatric Neurology Surveillance Unil IBPNSU) In 2(A)6, the BPNA sel up Ihe BPNSU to target surveillance of rare neurological conditions in a cost-effective and efficient manner wilh the sample population being UK consuliattl members of the BPNA. Since 2006, 28 studies have been conducted using BPNSU. Dr Sukhvir Wright has taken over from Prof Richard Chin as BPNSU Lead in the Research Committee. During 2023-24. 1 project was added onlo the BPNSU system (2022-23 0, 2021-22 2018-19=1. 2017-18=3). As of 31 March 2023 two projecls were active on BPNSU system. 1, 2020-21 =1, 2019-20=1- BPNSU fees We￿ inctrased in 2020-2110 £1,200 for up lo 2-years, which is still significantly less than oiher surveillance sludies. Additional years are charged £6(X) per annum. The BPNSU website has been moved inhouse since summer 2023 and has been managed by BPNA. achieving ¢onlinued update for the BPNSU email list and optimisalion of returns by the Membership Manager. Emails are sent out once a month for notifications of new sludies. In 2020-21, an audit of all past stLidies was carried out. Since 2014, there have been 15 conference absiract5 and 10 peer-revi¢wed publications resulting from BPNSU studies. Journal publications have been in Developmental Medicine and Child Neurology, Neurology* and Lancet Child and Adolesceni Health. One PhD was awarded, and one Project reported 4 invited international talks in which BPNSU data were parn of the presentation. There were four 9uccessful grant applications arising from BPNSU studies. with a lolal grant income of £1,237,949.. 1 MRC Developmental Pathway Funding Scheme award, l NIHRIGOSH Clinical Fellowship, l KESS2 (Knowledge Economy Skills Scheme) Siudentship. and a donation from the Alternating Hemiplegia of Childhood UK Charity. Public engagement varied from parental groiips inforniing study design, results informing genetic counselling for families, to results being presented or planned to be presented. In 2021-22, the BPNA reviewed barrieis for applications and implemented the BPNSU Grant Award. It was agreed by the BPNA Trustees to produce a BPNSU Grant Award for up to a 2 year study. This is eqiiivalenl to ihe cost of £1200 which would cover the cost of a study 50 as lo suppori this charitable aim. This grant would be eligible for a BPNA member who is otherwise a trainee or newly appoinlmenl consultant within 2 years of qualifying. The purix)se of the award is to promote research amongst junior members of ihe BPNA and to help create future researchers in paediatri¢ neurology. Recent aims has been lo promole BPNSU lo develop our relationship and try to collaborate with the British Paedialric Siirveillan¢e Unil IBPSUI which is parl of the RCPCH. This is due lo having similar objectives and is ongoing. Page 12

British Paediatric Neurology Association Report of the Trust¢ ror the Year Ended 31 March 2024 5.2 Paediairic Neurolo FLllow.qlii A partnership was established in 2015 with Action Medical Research (AMR) io jointly fund a 3-year AMR-BPNA Research Training Fellowship. Voluntary donations of members and income generated from sponsored symposia at the annual conference fund this fellowship. The second fellowship has been awarded to Dr Michael Eyre. Hi5 3-year fellowship was due to commence in September 2020, howevei. the start date has been deferred lo March 2021 due lo Covid-19. In his project, 'Developing magnetic resonance measures of neiirobiological dysfunction in early recovery from NMDAR-anlibody encephalilis,, Michael will investigate if advanced MRI techniques Can help predict recovery from NMDAR-antibody encephalitis in children and young people, paving the way for new treatment approaches for the condition in future. The third fellowship wa5 advertised and awarded to Dr Jonathon Holland, commencing in Autumn 2022. In his project; Muliiple sclerosi8: assessing nerve repair in cliildren lo find out if they could benefit from new Irealmenls, Jonathon will aim io find oul wheiher children with MS could benefit from potential new trealmenls currently being tested in adiilts. A fourth Fellowsliip was advertised in Summer 2023 with the aim lo commence in Spring 2024. However, candidates were not considered up io the standards and therefore the fellowship was not awarded to anyone. The fourth Fellowship will be advertised again in Summer 2024 with the aim lo commence in Spring 2025. The BPNA Research committee has designed a pre-selection questionnaire to support appli¢8nts. Previous AMR BPNA Research Training Fellows.. 2016-19 Dr Aposiolos Papandreou Neurodegeneraiive disorders with brain iron accumulation - finding new treatments. 5.3 BPNA Conference The BPNA Research Commit￿e review, score and select submilled abslraclg, sponsored symposium and the Ronnie MacKeiih Prize. Mac Keith Press co support the Ronnie MacKeith Prize and also support and se1￿¢ the Developmental Medicine and Child Neurology (DMCN) Best Article by a BPNA Trainee Prize. Prizes are also chosen and give by the BPNA for the Besi Poster by a Trainee Prize. Best Poster Audio Narrative by a Trainee Prize, Best Oral Presentation by a Trainee Prlze and Best Medical Siudent Presentation. 5.4 Read of Ilie monili aiid Traince nf Ilie niiinili A5 part of the BPNA Newsletter, every month, a different member of ihe BPNA Research Committee will choose a recently PLiblished. topical paper relevant to Paediatric Neurology, Neurodisability or Neuroscience, that Ihey think woiild be of interest to the BPNA membership. Also every month. a recent publication that has either been led by a BPNA Trainee (or where a Irainee has provided significanl input) will be highlighted. 6. Professional .Su rt There is a high demand for Professional Support. One full lime slaff member Imembership Manager) oversees the department. Dealing willi menibership requests, mentoring capacity, organisaiion of meetings for Special Inieresi Groups and supporting Trainees with (heir development. The Professional Support Officer (Trustee) is responsible for the department and meets regularly with the Membership Manager and Director to make sure areas that need development are progressing including job planning, mentoring, charity involvemenl (PPI). Census and Paediatric Neurology recruitment. Page 13

British Paediatrie Neurology Associatlon Report of the Trn$te¢5 for the Year Ended 31 March 2024 LI BPNA member%l)i Membership numbers have inereased sleadily during 2023-24, supported by the Membership Manager, Katerina Roumelioli. A new eategory of membership 'Allied Health Professional, was introduced in recent year.8. This category has minimal subscription fees io encourage engagement and no voting rights. The BPNA also added Medical Studei)t membership with £0 fee to engage with young people with an early interest in Paediairic NeLirology. Criieria to be accepted is a confirnialion letter from associated University thal i.q resent each year for membership renewal. BPNA Membersai March 2024 700 5(Al 52 Icw 14 )ni 16 ?ni? ?n1P ?oJn )n?t ?0)4 ?n?4 nrAlnary # n¥•r￿ls Membership Numbers 2024 2023 Catsgory Ordinary Overseas 2022 382 376 342 75 72 72 Trainee 125 126 118 Senior 70 66 Honorary AHP 10 51 26 Medical Student Total 715 705 636 Page 14

British Paediatric Neurology Association Report of the Trustee5 for the Year Ended 31 March 2024 (1.2 Mciiloi'iii ,Ind TLcllil Sli )orL In 2015-16 Trustees identified a need for members to have access to mentoring services, and it was &￿eed that ilie BPNA shoiild Contribute to fLilfilling this need. The nientoi'ing programme began in 2016. During 2020-21 the mentoring programme was expanded lo p4ediatric i)ellrology and Neurodisability GRID irainees wiiliin 12 Tnonthb of ccr to piovidc additional supporl through the pandemic. As of 31 March 2U24, Ih¥tL (LfL 42 BPNA mcmbcrs volunteering as mentors (2023-39) wilh 29 mentee.q (2023=50) wilh mentors now taking on two mcntee.q. In Novcmbcr 2023 BPNA COTllTlliS5ioned a Mentor Consultant lo deliver a training day for menlors for a fourth lime. The tt7ining tiiught different models of menlorship and wa% Ycry well rC￿lvcd. Th¢ ahm woiild bc lo do ihis evcry year but rcvicwing developniciit for both mentors and mentees and how ihis area can evolve. DLiring. 2023 ibc Tnenloring programme w(￿ cxpanded for more senior CPN8 who requEsled Tnare Tnentors lo support Ihcm through career stageb, such as post moves, return from parental leave, rel1￿Me￿l etc. The mentoring and iiientee program is being reviewed in was it can be developed for the workforce of the BPNA membership. Invited Reviews In Slipport of the BPNA charitable aims, BPNA Invited Reviews offer assistance to healilicare organisations in addressing concei'ns and ¢liallenges relating to care for children with neurological ¢ondilions. "The primary pui'pose of an invited review is lo piovide expert opii)ion and external assurance around quality of care that may lead lo improvements lo patient safely and service provision. Invited reviews are designed io facilitate reflection and learning. Academy of Medical Royal Colleges 'A framework of operating principles for managing invited reviews within liealthcare, (March 20221,. BPNA Inwiled Reviews are conducted in accordance with the principles sel oiil in the Academy of Medical Royal Colleges (AOMRCI 'A framework of operating principle5 for managing invited reviews within healthcare, (Marc11 2022). The BPNA has prodiiced A GLiide to BPNA Inviied Reviewb, available on the BPNA website, which explains the slrLiclured, clear and consistent process that we lollow. No Invited reviews happened this year. Page 15

British Paediatrlc Neurology Associatlon Report of the Trnstees for tht YeAr Ended 31 March 2024 6.3S ecittl Inlcre%t Gioii .qIVi For the SpLcial intcrcst group.s hybiid working makes it mole accessible for people to join online or person depending liow their meeting is arrangcd. Some face-lo-faLc meetings happen but due to the 8i/.c of the group% onlinc meetings arc more beneficial for peoplc lo attend. The BPNA also iipdaled their website for each SIG page to inform about Trials and i"esuurcc documeni% r(Ir ihcir members. 6.4 Bi-ilisl) P<iedi<iifiL F. ilL GI'OLI Mcnibers of this SpeLial Interest Group have particular expertise in childhood epilep%y. There are over 100 mcmbers which includcs pacdiatri¢ neur()lthgi.%ts, pacdiatrician.q wilh an interest in Lpilcpsy and clinical nursc specialA814. Thrcc mcctings have beeii hcld in June and Novembcr 2022 41nd March 2023. The focus of the nieelings ha5 becn on the development and implementation of guidelines for epilepsy in childrcn. to share updales in audit and research in paediatric epilepsy, to explore opportunities for the professionals to network and to discuss anonymised complex and ediicational cases. The BPEG IBrilish Paedialric Epilepsy Group) Chair and members have contributed to the following parti¢ular aspects of childhood epilepsy.. Cannabidiol and CBMPS Ongoing liaison with RCPCH, NHSE and stakeholder charities on issiies related to prescription of cannabis-based products for medicinal iise in children and young people with epilepsy. BPEGIBPNA have had meetings with APPG chair for prescription of CBMPS and Patient Safety Commissioner io discuss these issues. RegLilar BPNA CBMP group meetings to review press and media requests about CBMPS. Sodium valproate SinLe ihe announcemeni of MHRA statemeni on new restrictiong on the prescription of sodium valproale, we have actively engaged with relevant siakLh()Iders such as tpilepsy charities. A%%ociation of British Ncurologisl8. and OPF,N-UK to di8eu44 potential implicativns. We have wrillcn lo MHRA expre%sing our concern.4 potential ri8k% for patients wilh epilcpsy. and requested a mceling with MHRA to discuss our conccrns and sugge%livns tor safe impleTncntation OF any chan¥cs. We have also formcd a working group with ABN membcrs lo address the issuc of changes lo sodium valpn)aie pre%Lription. .Stakeholder Charities Eiigagcment wilh siakttholdcr charities. in particular addirsbing ihe issues of pre.%Lription of sodium valproate 1¢ nd CBMPS. NHSE Epilepsy Qversight group Provided oversight on developing national bundles of care for patients with epilepsy a5 pai'l of CYP Transformation Programme. Led on development of national bundle of care for transition to adult care for CYP with epilepsy. Faeilltating research in psediatric epilepsy BPEG provide5 the platform for colleagues from acro8S the UK io present their research, facilitate collaboration and setting up a dedicaied page on BPNA website with informaiion on epilepsy research projects.

Brit15h Paediatric Neurology Association Report oc the Trustees the Yellr Ended 31 M2r¢h 2024 C]inlcal Nurse specialists and paediatric neurology trainees B?EG have encouraged ¢ontribulion of clini¢al nurse specialists and Advanced Nurse Praciilioner in childho(xl epilepsy and requested for representslion in the group. B?EG have encouraged particlpation of paediatric neurology iraine¢s and epilepsy SPIN trainees and r¢quesied for rq)reseniation in the group. Additional meetings regularly attended with contributions from BPEG: Epilepsy 12 Audit programme. Open UK Network Meeting. Epilepsy Programme Board (led by RCPCH). RESCAS. 6 5 Cei'ebi'ovtl8ciil<ir S ecial Intere.41 GrnLI T.iis group s interest is in ihe clinical area of neurovasculai. disorders, such as paediatric 51roke and other vascular disorders a￿eCtIng the central nervous system. The lack of a database 18 seen as a major obstscle by colleague5 and efforts conliniie to resolve this. T.ie group men)bers are going to Tneet next in June and following that in the autumn. Dr Alwis has accepted lo be the group's secretary and we a150 have trainee representatives within (he group. I'e continue to work alongside the Stroke association in highlighting the inequity of slroke care in some regions and inproving access to treatments in a timely manner. 1.6 Childreii'$ 14Lad41¢1ie Neiwiirk Cl-liiN CIIAN has continued io remain very active over ihe past year to advance the clinical management, educalion and research ir. primary ai)d %econd&ry childhood headache disorders. Although there is an appeiile lo resun)e face to face Tneeling. we plan to have the next meeting in autumn 2023 as rc.mot¢lvirlual. There remain5 a clear 51ructure of the role5 Wlthin the CHaN network on a narional level with dedicaEed responsibiliiies io n-.embers for providing clinical, research and acadeTnic updates. CHaN also recognises the need to develop national regislries for patienls with conditions like Migrainel TACS and U1common headach¢s. Specialist groups within CHaN such as IIH SIG group and the CHAT course development network ci)ntinue to develop educational materials and guidelines le.g., Ihe paper by Holland et al. on 'How lo perform Lumbar p.InctLire in children. and the paper by Dr Prabhakar et al. regarding the 'Assessment and management of children with aLUte headaches,) both recently published in the Archives of Disease in Childho¢)d _ims for the next year: Benchmark the ciirreni practice for management of episodic and chronic migraines in the UK with identification of key paediatricians, so that a gap analysis can be made Closer and wider engagement with various Iieadache charities {like The Migraine Trustl The Brain Charity) to fund data bases and educational tools Encourage iraineeb, participation in the distance learning module Page 17

British Paediatric Neurology Association Report of the Trustees ror the Year Ended 31 March 2024 . l. Fctal & Neunalal Neurolo Spccial Iiitcrcst Grou The PLrinatdl Special Jnlcrcsi Groups haq a sliong edlicalional theme, and continues to provide educalional meeiings twice a ycar in neonatal and fctdl neurology. Thesc have been dclivcrcd virtually %incc the COVID pundemic. and draw a range of health c￿e prol'essionals, including Iherapiqis and nurses, IroTll around the UK and beyond. Mcmbcrs of Lhe SIG have worked with ihc BPNA executivc to relaunch ihc NeoNATE cour.%c. which was on hold following ihc pandemic, and two courses are planncd in 2023-2024. Wc are looking lo increase our tcaLhing faculty iii the coming yLar. We have had a initial planning meeting for the BI'NA Fcldl coiii'se. whiLh aims to providc cdiicational matcrial on fetal neurological anomalies and antenatal counselling. A preliminary programme has been pr()duccd and talks ai"c currently belng wriltcn. We plan io meet in Autumn lo rcview progress. Inteinatii)nally, we have had Tneetings with perinalal neurology ¢ollcagues in Ihe US, and plan to collaborate on edii¢aiion meeting8 and sctvice recommendations. as well as building our contacts in Europe. Wiihin the UK, we have continued our work with the British Association ol Perinatal Medicine on gliidelines, on this occasion recommendaiions for neonatal neiiroimaging. Clinically, the BPNA exe¢iilive has agreed for us io proceed with an illiliative to develop patient informaiion leafleis on a range of fetal neurological anomalies, and a working group is being created. We also intend to discuss how we can collect data on genetic diagnoses and outcomes loo, which would infom) and improve future prognostication. Menibers of the SIG remain research active in a range of ideas. including MRI appearances and neuro-developmenl ouicomes following neonatal hypoxic ischaemic encephalopathy, families, views on anlenaial counselling, and a new profoma for the neurological examination of the unwell newborn baby. 6.7.2. Inlicriled Wliite MaiiLr Di%ordei's LLuki)(I New National Service for Inherited White Matter DSsorders (IWMD) elinical registry NHS England has recently commissioned a ncw highly specialised service for Inherited While Matter Disorders IIWMDS) and also a separate National IMWD clinical registry lo siipport ihis. NHSE has commissioned 3 paedi¥?Iric and 4 aduli centi'es to provide the IWMD service. NHSE has albo contracted with Evelina London Children's Hospilal which is part of Guy's and St Thomas, NHS Foundation Trusi, 10 hosi the Naiional IMWD clinical registry. A core element of the registry is the managemcnt of online gcLure databasc thal contains information about pcople of all agcs with suspeclcd or confimiLd IWMD. We aivn lo iise this registry to support the provision uf direct paLienl trcatment and care and improvements lo clinical carc. This will help us to.- undcrstand the inLidcnce and prcvalence of IWMD in our population. improve t)ur understanding of the naiural history of vurious IWMDS, mcasure ihe impact of Ilving with an IWMD for paticnts and carcrs and create morc awarene45 (Trf these conditions. Thi5 regi.glry is Uniqlie as this is both clinician and patienl drivcn. The primary aim of this registry iq for clinical purposes. however, this Icgi&lry will ccrtdinly provide importani daia for future rescarch for patienls wiLhin the ficld of IWMDS. The regiqlry will work very closely with 3 other paedialric IWMD clinical service ccnlres ILeedslManche8ter- lid by Profcssor John LivingslonlDr fjipdk Ram, Birmingham led by Professor Evangeline Wassmei. and t)r AJnitav Parida and London (GSI'T and Great Ormond Street) lcd by Dr Rahul Singh/Dr Cheryl Hemingway) and the aduli cenlre {London, Queen SqU￿.e Hospital-led hy Dr David Lynch) in collaboration with units in the north dnd Midland%. A formal launch of the IWMD I'egistry servA¢e will lake place laier in the year. The registry is in the piloi phase now and we expect this will be live soon. We would accept referral.s from patients, parents or carers, clinicians involved with the IWMD patients, and frotn iieurologisls. paedialric neurologists, geneticists, metabolic physicians, geneticists, paediatricians or any local Clinicians involved in the diagnosis or treatment of IWMDS. Referrals will also be accepted from fetal medicine ieams, when ihere is a strong family hisLory of an IWMD and we will also facilitate rapid diagnosis for conditions where ihere is a ireattncnt option (c.g. Metachromatic Leukodysu'ophy). Page 18

Brltish Paediatric Neurology Association Report ol the Trustees for the Year Ended 31 March 2024 The charities Alex TLC (www.alextlc.org) and Metabolic Support UK (www.melabolicsupporluk.org) have been closely involved in the development of this regislry, will continue lo support the registry and will be an integral parl of the IWMD registry steering and development committee. We plan that Ihe new service will be fully operational in the coming months. In the meantime, if you wish to request fuiiher information ple&se contact.. [e-mail] 6.7.1. Bi'iLi.%li Paediati'ic Movemenl Di%(Irder S eeial InlbrLS1 Groi The last year has been an a¢tive and successfiil year for the SIG. In addition to regular virtual meetings. the SIG held a well-attended meeting al the Bristol Conference focussing on the development of guidance for parents and carers on video recordings of Movement Disorders. This was in addition to a very constrnctive Research focused meeting on how lo address the findings of the BPNA Priority setting Project. The SIG will continiie to me¢t largely virtually for 202412025, with at least one FIF meeting al the next BPNA Conference in Oxford. Education continues to be a major focu.s of the MDSIG. Thi5 year saw the successful launch of the MovEd course. delivered by an expert faculty led by Dr Lucinda Carr. The fir51 course ran over 2 days in October 2023, with excellent feedback. We thank Il)e faculty for all of their hard work producing such an excellent educational resource. The ACT course has wntinued to run with similarly excellent feedback. The course leads are committed Lo expanding the faculty of boih cours¢s, and I would strongly recommend this to MDSIG members as an extremely satisfying experienced. Focus will now tun) to completing the over-due re-write of Unil 4 of the Dislaiice Learning Course, along with the developmenl of ihe planned Expert-to-Experl Movement Disorder course. Work has continued on Guideline Development. The Consen%u5 Standards on Medication Use in management of Childhood Dystonia project has launched, and al the lime of writing is close lo completing the initial stage of Collection of suggested standards. This project, sponsored by the BPNA, is a joint venlure with the British Academy of Childhood Disability and the Association of Paediatric Palliative Care Medicine. along wilh other stake holders. The next stage will be to undertake a Delphi process based upon tlie suggested standards received. Similar work around the referral of children for consideration of neurosurgical interventions will move shortly to Il)e Delphi stage. A FtF meeting is planned later this year io begin to exploi'e patliways of care for Children and Young People with Reli Syndrome in light of the emergence of gene therapy trials for this condition. Members of the SIG have expressed understandable concerns about the stability of supply line for commonly used medications. Discussions Continue with the Neonatal and Paediatric Phamiacy Groiip and colleagiies across ihe BPNA and the Association of British Neurologist (ABN) about how best to "horizon scanning" for such problems. The SIG 15 currently Iindertaking and audit across several centres on the use of transdermal clonidine patches and is supporting the development of guidance foi. the use of patches. Work with transltion has progressed. The BPNA and ABN have re¢ognised this as a priority, and will be hosiing a FtF meeting later this year lo identify areas of priority for both groiips. The MDSIG will be well represented at these meetings. May 2025 will be the end of my second ￿rM as Chair of tl)e group, aT]d throughout the coming year we will be looking to identify a replacement Chair. Dr Raj Lodh's second term as SeciElary will also being coming lo an end at ihat time, providing another opportiinity for BPNA members lo contribute more forn)ally to the working of the SIG. 6.7.4. MLI.4cle Iiilei'esl Gi-oii The muscle SIG works closely with the neuromus¢ular charilies, in pariicular the Muscular Dystrophy UK {MDUK), Aclion Duchenne, Duchenne UK. SMA UK. DMD HUB. These parinerships have helped accelera￿ research - funding research fellow posts, access lo clinical trials, improved Siaffing at peripheral sites for trial set up, helped coordinate regional neuromuscular networks and upskilling events and Slipporled meelings lo improve standards of care and data colleciion and dissemination. The centre of excellence audits took place in 2023 and were awarded to ¢¢nlres in 2024. 24 ¢enire awards in lolal. 16 10 those with clinical excellence with research. 3 with clinical excellence and 6 pursuing awards in clinical excellence +l- I'esear¢h. Page 19

British Paedlatrle Neurology Association Report of the Trnstees for the Year Ended 31 March 2024 This year key involvements have been with SMA UK and MDUK in helping to Continue the delivery of the MDT in SMA. including Zolgensma, risdiplam and nusinersen following approval by NLCE NHSE on 8 March 2021. The lasr 12 monihs have been focused on working towards newbom screening whi¢h will change the prognosis and ouicome8 for the children with SMA type l. The infusion sites are well established and the national MDT rlinning since May 2021, and over 100 ctlildren have received gene therapy. All ihe SMA children have been followed up and various webinars and meetings have been held with ELiropean colleagueq on side eff￿(S and problems aSsocia￿d with gene therapy, as well as forum meetings face lo face planned in June and November 2024. From the Norihsiar group., Work has been conlinuing on AialuiEn and enabling access for this drug after EMA renewal was not siiccessful in September 2023, but NICE approved Ataluren 22 February 2023 via HST22 committee. There are also ongoing submissions to NICE and NHSE for Vamoi'olone and Givinostal, both non-mutation specific drLigs for DMD. HUB DMD. has continued close working with clinicians to enable trial readiness and liaison with the pharma companies to look at what is needed per sile to continue trials. Trials are now continuing and furiher set up of sites for new studies liave commen¢¢d. As a SIG we have coniiniied in 2023 and 2024 10 meet regularly virtually and full day face lo face muscle interest group meeting planned for 14th June 2024. Both paediatric and adLilt Northsthr meetings IDMD) and paediatric and adult SMA REACH meetings (SMA) have continued virlually thig last 12 months, especially developing the adult SMA REACH. British Myology socieiy was face lo face as was the Translational research meeting UK and World mLiscle society meeting. The muscle interest group has met 4 times in tolal 2 fully virtually and 2 meetings face to face Iparl of BMS and standalone day in June 2023) for case discussions and iopic led presentations over the last 12 months. The RDCN (rare diseases collaborative networks) accredited the Juvenile Myasthenia (JMG) Gravis group in 2023 and this continues to be hosied by the designated providerg. Oxford specialist service, and this groiip io have virtU81 meetings for dtfficult cases with JMG. The charities also sponsor, the muscle group's main annual meerings such as the British Myology society. Translational research meeting UK, Northslar and SMA REACH meetings within the UK. The meetings also receive unresti-icted educational grants from pharmaceuLical companies. We work together with the clinicians on various paiient iniliaiives- patient leaflets, e-learning modiiles, patient days, Children's transiiion days and camps- and support the various neuromus¢iilar ￿amS in their individual areas. such as NM networks, local educational meetings and trial set ups. Lastly, we are working with colleagues both trainees and Consuliants to lake a closer look al training and how we can increase opportunities and interest in training in Neuromuscular disorders. This year we have appointed a MIG trainee representative Dr Alison Skippen and at our next face to face meeting on the 14th of June in Birn)ingham. we have a session dedicated to discussing this aspect. 6.7.5. NeiiroLiilanLous S Cl&il IiilerLs1 Groii This groiip's interest is in the clinical area of neumcutaiieoiis syndromes. such as Neurofibromalosis, Tuberous Sclerosis Complex and Sturge Weber Syndrome. This is a relatively new group who has been running for about iwo years. We are meeting twice a year which are a mix of viriual, hybrid and had an in-person meeting during the BPNA conference ihis year. The neurocutaneous SIG has been supporting paedialric neurologists and paediatricians across the country with informaiion about ihe different syndromes. Members have been involved in supponing and giving information to stakeholders and io families ai support days hosted by charities. We have algo Completed a survey into the use of vigabatrin iwb TSC and will be discussing next sleps in our next meeting. As a group we are keen to discuss and share informalion about upcoming research and new Irealmenis. We are keen to hear from leading experis from across the UK lo share knowledge and experience. Page 20

British Paediatric Neurology Assoclatlon Report of the Tru5lees for the Year Ended 31 March 2024 ACHIEVEMENT AND PERFORMANCE FundrAlslng actlyitles 6.7,6. Ti'aiiiees, S CLIJI Ii)ierL%I CJrL)u The BPNA Iraine¢%' special inlcrcst group ISIG) is a group for all BPNA trainee members and those interesied in paediatric neurology training. Currently there are 129 Trainee members, including paedialric neurology subspecialty trainees (GIUD), paediairic trainees of different grades, and other Irainees interested in paediatric neurology. The group meets twice a year, once ai ihe BPNA conference in January and once al a 2-day educational trainees, meeting held in May. In May 2023 our meeting covered Paediatric Neurogenetics, in which our excellent speakers educated on all things genomics, geneiic Iherapies. and neurocutaneous syndromes. The Stuart Green Memorial session was a maslerclass on clinical examination in paedialric neurology given by Dr Peter Baxter. We have just concluded the May 2024 meeting which was split between an update on Neuroinflammation, and a Research Matters training day. Prof Ming Lim gave an inspiring Stuart Green Memorial lecture, and we enjoyed talks and inleraclive sessions from an excellent speaking line up. For boih years. over 40 attendees were present, mostly in person, and all enjoyed an excellent dinner and social evening. We are very grateful to the many excellent speakers who gave their lime for Ihese events. Recordings of sessions are available to watch An the BPNA Trainees, SIG area of the BPNA websits. The Research Matters training day deserves further mention - this was co-organised with Dr Sukhe Wright and the Research Committee, and we are very grateful for the support of Dr Sam Amin for this day. The 30 attendees in person and 12 online heard a wide array of inspiring speakers, and participated in workshop sessions on developing a research question and writing a research proposal. The faculty included BPNA research Committee members, consultant paediaLric neurologisis, an expert on PPI neurological disorder lived experience, members of Action Medical Research and Epilepsy Re5ear¢h UK, and trainee members. The SIG a180 contributes lowards the BPNA Recruitment working group aiming lo improve recruitment lo paeiliatric neurology specialty training, We continue lo run annual pre-appli¢ation and interview webinars for neurology and neurodisability applicants, which have been well-received by EK>th applicants and CSAC interviewers. Recordings of these sessions are available on the BPNA website careers section. Overall, recruitment has moved into a differenl phase, with a higher applicant lo place raiio than previously rel]ecting in part the efforts of the working group - this is a good time to put out a specially training post, so please do work wilh your deanery training programme directors. In Oclol)er 2023 we ran a first joint event with ihe siudenl group NANSIG who have presence in every medical school nationally - this Saturday morning online session was attended by over 50 interested medical students and foundation doctors. In addition, medical students can now join the BPNA for free. and we are working lo increase inleresl at earlier stages of training. We will continue to work with NANSIG to extend our reach with do¢tors and tnedical students at an early stage, to increase awareness that neurosciences can be fruitfully pursued within paediatrics. The results of the 2023 paediatric neurology subgpecialty training annual survey were presented at an RCPCH CSAC meeting and aT] anonymous summary of resiilts was sent to all training ¢enlres. Issues highlighted as of particular concern lo training include workload difficulties. difficulty accessing several ar¢as (neonatal neurology, neuropsychAatry, and adult neurology). limited access to clinics, and limited or inequitable access to research opporlunilies. With CSAC we continue lo work on these issues where possible and support individual trainees al and between their annual review meetings. The SIG continues lo successfully set up and support study groups for modules of the BPNA Distance Learning. Trainees report Ihese provide excellent support and motivation lo complete modules. The groups are open to all trainees and recent groups included neurology specially trairsees, epilepsy specialist inlerest (SPIN) trainees, trainees from abToad, and recenily qualified consultants completing units lo complete SPIN accreditation. Many of these groups have very kindly been supported by consultanLs offering their lime lo supervise and facilitate the sessions during their weekly meetings. Finally, we would like lo congratulate the election of Dr Aiidrey Soo as chair and Dr Abigail Lazenbury as depuly chair of the SIG going forward. We were very pleased to have eight applications for the roles, reflecting the engagement and enthusiasm amongst our paediatric neurology trainees, and Tom and l are confident the SIG 15 in excellent hands going forward. Page21

British Paediatrle Neurology Assoeiatlon Report of the Trustees for the Year Ended 31 March 2024 ACHIEVEMENT AND PERFORMANCE 6.7.7. UK-Cliildliood Inlldiiiiiilllor Deni This group's interesi is in the clinical area of acquired intlammaiory white matter diseases (such as paediatric onsei Muliiple Sclerosis, MOGAD and AQP4 antibody driven disorders and the autoimmune mediated encephalitides) as well as other less common inflaTt]matory brain conditions. The past 12 months has continued to be a busy for the paediAtric neurology acquiiEd and inflammaiory whitc matter group. We have met regularly, as before, every 2 months. The meeting5 have all been virlLial, chaired by Paed Neurologisi Cheryl Hemingway and with administrative support provided by the BPNA and hosted on the BPNA Zoom platform. Clinical adniinistralive support has been provided by GOSH PA team. The 6 meetings have been well attended, wilh arnund 40- 50 individuals joining, wilh both national and iniernalional represenlalion. The meeting forniat has continued as before, with the fjrst hour ¢onsisling of upda￿S and formal presentations, and the next 3 hours discussing clinical cases. We have dAs¢ussed on average 10-12 clinical cases pei. meeiing. The meeting has been excellenily supported by expert neuroinflammatory colleagues around UK and has had expert neiiroradiology from Giral Ormond Street. and we thank partieiilarly Dr Kshitij Mankad and Dr Asthik Biswas for iheir time. We have as before kept the formal slandard as follows: 3rd Friday of every 2nd month Time: 1-5pm Video-conferencing via Zoom First 60-90 minutes involves updates on researchlnew medicationslclinical challenges then Brief comfort break Next 90 minutes discussion of clinical cases with radiology review and forniulation of a suggested invegiigation andlor Ireatmenl plan The meetings have all been experily documented, and I would particularly like lo thank Dr Eyre, Dr Abdel-mannan and Dr Perry and Dr Holland. We have in tlie meeting had a number of excellent presenlaiions and also had regLilar research updaies from the fellows in neuroinflammation. The talks at the meeilngs have been recorded and are available on the BPNA website for ihe SIG members. In May 2023 Cambridge hosted the UKCNIDINHS England HSS (Highly Specialised Service) paediatric onset MS me¢iing. Atlendees included Paediatric Neurologists, trainees in neuroinflammation, specialist nurse,s, researchers and NHS managers from Birmingham Children's Hospital. GOSH, Evelina Children's Hospital, Royal Manchesler Children's Hospital, Addenbrookes, Alder Hey aT]d NHS England, University of Oxford, and Birmingham University. The disease management guidelines, patient inforn]alion sheets and disease modifying drug gLiidelines were also compleied and many have been uploaded lo the NHSE Plaiforni We will conrinue to meet over the nexi 12 months. with another face Éo a face meeting planned for May 2024 and hosted this year by Manchester. The next 12 months the dates we are due to meel as follows.. 17 May 2024 (national meeting Manchester) 19 July 2024 13 September 2024 (moved because of EcfRIMS meeting) 15 November 2024 24 Janiiary 2025 Page 22

British Paediatric Neurology Association Report of the Trnstees for the Year Ended 31 March 2024 ACHIEVEMENT AND PERFORMANCE (?,7.8. LIK NeLlI'oreliiibilita(ion .S eLial Inici'csl Groii The pa¢diatriL neuroirhdbilitalion SICJ is a mul¢JdisLiplinary group supported by represenlalivcs frojn England. Scotland. Wales and Northcm Ireland. We aiTll lo.. Share gn(Kl praLIiLc Dcvclop an cquitable paedialric ncurorchdbilitation service nalionally Support rescarch and improve the evidencc base in paediatric neurorehabilitation for acquired CNS injury. Link Wilh other groups (third seclor) and parents l users affected by acquired brain injury Tlie SIG continiies to be Cliaired by Dr Peta Sharples. This year we have continued lo work closely wilh Ihe Paediatric Neuroscience Clinical Reference Group whose agenda priority is currently Paed Neurorehailitation. Paed CRG Neurosciences ich of our meetings has heard updates from the CRG Chair (Charlie Fairhur5t) and Anthony Prudhoe (Women and Childrens NHSE Manager) relating to the review of the National Service Specification for Paed Neurorehabilitaiion. In order for them to be satisfied this specifiealion review will meet the needs of our CYP population they have had significant engagemeni with our providing teams and visited several unils. We await the final consulialion. Meetings Kings Dee 2022 (Host) - theme paediatric spinal cord injury and the national transformation review. Speakers included Dr A Graham Services for CYP with acquired spinal cord injury - several units described their new Children's Spinal Cord Case Manager pos(s and Ihe London team ( speaker Anna Majowska ) shared Iheir SCI commi85ioning strategy. Oxford Mareh 22 (Host) - theme innovative tcchnology on applied lo Acq brain injury, including immersive virtual reality sy.slemb. Jill Cadwgan Spoke about Ihc Twoean Study A pioof of concept sludy of using wrist worn accelerometers lo enLouragc affected Lipper limb Tnovcments in children wilh unilatcral cerebral palsy. Infonndlion was also shared aboul ihe NIHR Innovation Observatory hurizon scanning research rc¥uiding tcchnology for Paediatrie TrauTna care and Rehab. Ncxt meeting Aulumn 2023 Date tbc. Areas of ongoing concern (amongst many) bcing itansition with a childhood ABI to aduli hood and also the challengc of finding optimal servicc5 if 5Ublaining an acquitted brain injury bclwccn 16-18 . 6.11. Clinical Governance IIPNA has been conslilied hy NHS NICE lo comment on gllidclines and quality standard% and by NHS F.ngland lo comment on Ihc ncw ijrug Irealmenls. If you would likc niore informauon about which ol these the BPNA have contribulcd please contact the Director. Internal and external factors Ri.4k niaiia The trustee% have assessed the major strategic, business, and operational risks to which the Association is exposed and are satisfied iliai syslems and procedures are in place io monitor and contro_l those risks to miligate any impact they might have on the Association. A risk register is maintained and updated regularly. Page 23

British Paedlatrlc Neurology Association Report of the Trusteos for the Yesr Ellded 31 March 2024 ACHIEVEMENT AND PERFORMANCE PrinLi al risks wid UiiLei'lJiiilie We have currenlfly idcntified the following factors as being the main risks io the BPNA.. Pressure from NHS Tru%ts on 14PNA members lo incrLa%c ihe number of elitlicslpaticnts and limil other activitics. This has ihc potcniial lo impact on ihe vulLintary time given by BPNA membcrs to lecture, tiitor and mcntor at short-courses, dislance-learning, aiid nicntoring. Our consultant members have remaincd robust and enthu.qia%lic in Ihis support, and we hopc that this will remain the c&qe, but il is clear that the BPNA would be unable to conliniic i delivering edlication withuui thi& gcneroiisly donaled lime. This is being monitored by Educ<ltion, QLiality & Standards committcc and Professional Support Commillce wilh (he aim lo start a faculiy retention workin¥ group this year to research and review the risks. Repulalion ITr bcing associated with unprofcssional or unethical or even criminal a¢livilies in the UKlabroad due lo disengdgeTnent about hot tOPlC ISSLies. Thi% can bc hi￿]I1ghted in recent ycars on cannabis-ba,sed medicinal producls (CBMPs} and Pdediairic A¢iite-Onset Neuropsychiatric Syndrome (PANS) and Paediatric Autoimmune Neuropsychiatric Disorders Asbociated with Streptococcal Infections {PANDAS).The BPNA has worked hard tn engaging with such issue5 and producing Iheir own or collaboration with other professional colleges to produce working slalemenls..5imilar issues will no doubt arise in the future and the BPNA must engage with those groups to be seen as professional and supportive while noi putting Jnore pressure on the BPNA members and wider medical professionals in the paediatric neurology community. The BPNA should hawe been historically VAT registered and there is a review by the accountants on how much will need io be paid back to HMRC. This will change the balance of Ihe reserves by next financial year and operational objectives may need lo change FINANCIAL REVIEW Finaneial position The balance sheei posiuon shows net cu￿en1 assets of £942,150 (2023 £922,236}, resulting from a stgntficant increase in the cash al bank co £1,053,537 12023 - £981,135). T1)is has been accompanied by an increase in debtors 10 £65.203 (2023 £40,051 I, and increase in creditors to £185.253 (2023 - £110,01 I ). At the year end the charity has unrestrieled freely available current reserves of £764.45912023 £909,160) which excllides (angible fixed LsseLs of £21,243 (2023 £10,402). Givcn thc Lharily's curreni levcls of expenditure this would allow for approximately jusl uvcr seven months 12023 icn months) of trading without further freely availablc reserves becoming available. Principle lunding sources Th¢ BPNA raisc5 funds mainly through payments received for Ils cducational activities, which include shorl-coiirses. annual confercnLc, unlinc distance-learning COUTSC. member.qhip subscriplions: and .qponsor.%liip. We have also raised money through the voluntary conlributions of members. I'olal incoming resources for the year have increased lo £1,217,765 (2023 £1,154,406). This increase has arisen mainly from the increase in grants to £242,718 {2023 - £120,415). Donations and legacies have increased in ihe year lo £411,123 {2023 - £255,960). Sponsors of ils annLial conference symposiums generating funds of £66,000 (2023 - £66,000), and generating annual conference sponsorship income of £110,5(J) {2023 £90.000). See 'No(e 4 Donations and Legacies" and "Note 6 LncoTne from Charitable Aclivilies" within the notes lo the financial statements for a detailed breakdown of income received in the year. Investmen¢ policy #nd objectives The policy of the BPNA is to invest ils reserves in the further development of ils chariiable aims. Page 24

British Paediatric Neurology Association Report of the Tn￿tee$ for the Year Ended 31 March 2024 FINANCIAL REVIEW The BPNA has also committed reserves lo the sustainability and further developmenl of both the distance learning and short courses. As a result of recent financial perfottnanLe, derivcd from additional incoming resources, the currenl level ol" reserves Ihc BPNA holds cash balances amounting lo £1,053,537 12023 £981.135) and 18 exploring inveslmenl opportuniticb for the rcscrvcs. Any interest earned will be utilised for re8earLh projccls and othcr aclivilies in line with the BPNA charitsble objeclivc.%. Res¢rvcs policy The tolal funds held at the year end were £963,753 (2023 £932.638) and of which £178.051 12023 £13,076) is maintained within restricted funds for their delailcd purp05cs as dcscribed in the notes to the financial slaternents. Further details of reslricied funds are includcd wiihin the notes to the financial siaiement5. The BPNA implemented two external VAT reviews due lo our large income and making sure we are complianl wilh HMRC. li has been confirmed that we should have been historically VAT registered and we are now reviewing the cost implications. This will change the balance of the reserves by next financial year which could be halved. Overall, the financial position of Ihe charity remains healthy, though the trustees continue lo pay close aiiention lo the mix of acliviiies in order lo ensure that in trying io achieve 115 objectives it does not lead ￿ deierioralion in the financial stability of the charity or staff burn out. A substantial proportion of the reserves in the balance sheet are represented by the cash al bank and in hand totalling £1,053,537 (2023 £981,135) in order to facilitate the continued activities of the charity by holding highly liquid assets. The trustees regularly review the finances, budgets, and cash flows to aid effective stewardship of the charity. The trusiees recognise that the level of reserv¢s fluctuates during periods of inve.4tmenl by the charity and ensure an adequatc rc5crve is maintained. I'o this end, in 2023-24 the Irustecs increased an unrestricted ¢onlingenLy fund i0 £250.000 (2023 £2(K).(K)O) which is held in order to miligatc the risk of liquidity concerns. The trustees havc agieed the level of funds held in thi% ￿CLoU￿1 bascd on ihe equivalenl of five monih s Secrctariat salaries plus major overheads including Office rentals. 'fhi% puliLy 16 rcvicwcd every 12-months. Fund5 in deficit Thcrc wcrc no flinds in deficit as al thc financial rcporting date or ihe comparaliye fin&uJcial rcporling dale. UIURE PLANS During 2024-25 recruilmenl lo pacdiatric neurology will continue and relationship with other association5 and colleges will continue lo dcvclop IRCPCH & Association of Briti.sh Neurolngisls). The BPNA Strategy day will happcn in Scptcrnbcr 2024 in line with th¢ new BPNA President taking up their position which will inform ihe direction the BPNA should go operationally. PETI will be launched in Tunisia in November 2024 and in Singapore in early 2025. PET4ward will laun¢h in April 2024. The NeoNATE and CHaT courses will undergo a revision in June 2024. STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document The BPNA is governed by ils consiituiion, approved on 3 December 2014 and updaied at the AGM on 23 January 2019. Page 25

British Paediatric Neurology Association Repor¢ of the Tn￿teeS for the Year Ended 31 March 202A STRUCTURE, GOVERNANCE AND MANAGEMENT Melhod of xppointment of trustee5 The management of the Asso¢iaiion 16 the responsibility of ihe trustees who are elected by BPNA meTnbers and appoinled under the terms of the Consiilulion. When a new Trustee is appointed a procedure is followed under BPNA policies which includes TrLlStee eligibility declaration, sending a copy of The Essential TDJStee' guide. Conflicts of Interest policy and Declaration of interest form. They are also offered training. Organisational structure and decision-making The trustees meet four times per year (usually j￿uary. June. September. November) when rn0￿ in depth sirategic decisions and business matters are discusscd. Monthly Zoom mcctings are also held. Council is a larger body that mcets twice per year (January and MaylJunc). During 2018-19, Council was expandcd to include representation from cvery UK paediatric neurology terniary ccntre and the Chairs of ihe Special in(ercst gmups iogether wilh the representatives ¢o-opied from related organisalions. The purpose of Council is to ensure a good exchange of inforniaiion and ideas relaied lo the care of children and young people with neurological conditions and paedialric neurology ediicaiion and training between Centres and other key organisalions. Please see list of BPNA Council members below: Page 26

British Paediatric Neurology Association Report of the Trnstees for the Year Ended 31 March 2024 STRUCTURE, GOVERNANCE AND MANAGEMENT Members of BPNA Council Serving During 2023-24 Execulive President Sccrelary Chair, R¢s¢a￿h Chair. Education Quality & Standards Chciir, Internalional Education Direclor, Senior Mallagevnent, BPNA I'reasurer l)rofessional Support o￿lcer National Training Advisor Name Dr Ai15a MLLcllan Dr Danicl Lumsden Dr Sam Amin Dr Manali Chilrc Prof Martin Kirkpatrick Mr Philip Lcvine Dr SanLosh Mordekar Dr Manish Prasad Dr Dipak Ram 'I'erin F.x January 2027 January 2025 January 2025 January 2027 January 2025 January 2026 January 2026 January 2027 Pdediali'ic Neui'olo Belfast Dundee Edinburgh Glasgow Newcasile-Lipon-Tyne Liverpool Manchester Preston Leeds Sheffield Nottingham Leicester Birmingliam Cambridge Oxford Bristol Cardiff Ceiiires I'L.4eiiiaiivL Dr Donncha Harahan Dr Alice Jollands Dr Kenneih Mcwilliam (2nd Term) Dr Sarah Abernethy Dr Anna Basu Dr Rajesh Karuvattil Dr Siobh&n West Dr Christian De Goede (2nd Tenn) Dr Lydia Green Dr Archana Deskurkar (2nd Term) Dr Singaravadivelu Velmurugan Dr Nahin Hussain12nd Terni) Dr Annapurna Sudarsanam Dr Deepa Krishnakumar Dr Sithara Ramda812nd Term) Dr Andrew Mallick Dr Johann te Water Naude (2nd ierni) Dr Gcorgina Bird-LiLbcrman {2nd Term} Dr Sanjay Bhate (2nd Tenn) Dr Naila Ismayilova (2nd Terni) Dr Sushil Beri (2nd Ternil Dr Louise H￿lIcY (2nd Term) J)r Danicl l.um5dcn Dr Anlonia Clarkc (2nd Term) Dr Elma Stephen edr lerm January 2025 January 2025 January 2025 January 2026 January 2024 January 2027 January 2026 January 2025 Janiiary 2026 January 2025 January 2027 January 2025 January 2027 January 2026 January 2025 January 2027 January 2026 Southampton JJ)ndun= Grcai Orni<ind Sircei Hospital London- Chclsca & Wc6tminslcr Hospital London: Imperial College NFIS Trust London.. The Rnyal London London.. Evelina LA)ndon Children's Ho%pilal London.. Si CFeorge'8 Ho.qpitsl Abcrdeen January 2026 January 2025 January 2025 January 2025 January 2025 January 2025 January 2025 January 2027 eci,il Inl¢re%l Cilnu British Paediatric Epilepsy Group Cerebrovascular Children's Headache Network Feial & Neonaial Neurology Fetal & Neonatal Neiiiology The Genetic While Mai*r Disorders British Paedialric Movement Disorders Muscle Interest Group UK Neui'orehabilitation Chair Dr Suresh Pujar Dr Jaspal Singh Dr Gauiam Ambegaollkar Dr Anthony Hart (Co-chair 2nd TeThn) Dr Brigilfr Vollmer (Co-chair) Dr Rahul Singh Dr Daniel Lunisden12nd Term) Dr Tracey Willis {2nd Term) Dr Peta Sharples (2nd Tei'm) ear terin Junc 2025 Febru4iry 2026 January 2025 May 2025 May 2025 January 2025 May 2025 May 2025 April 2024 Page 27

Britlsh Paediatric Neurology Association Report of the TnLStees for the Yethr Etmled 31 Moreh 2024 STRUCTURE, GOVERNANCF AND MANAGEMENT UK-Childhood N¢uro-Inflammatory Disorders Di Cheryl Hemmingway Neurocutaneous Dr Sam Amin (Co-chair) NeuroLuthncous Dr Sarah Aylett (Co-chair) RCPCH SPIN Epilepsy Trainees Dr Manali Chitre (Chair) Trainees, Chair Dr Robert Spaull Trainees, Depuly Chair Dr Tom Smith May 2023 AugLisI 2025 August 2025 Augusi 2025 June 2024 June 2024 Co-o ted Fditor. DMCN British Paediatric Ncurosurgical Group Chair, Neurodisability CSAC Paediatric Ncuroscienqe% CRG Neuropqychiatry Rcpresentative Short Course Development Manager Distance Learning Development Manager BPNA 2025 Oxford Organiser Trainee Rep, Neurodisability Re. rL8cnlalive Dr Bcrnard Dan Dr Pasquale Gallo Dr Kaiherine Martin Dr Anita Dcvlin Dr Ashley Liew Dr Colin Diinkley Dr Louise Hartley Dr Sandeep Jayawant Dr James Hammond Co-opted Co-opted Co-opted Co-oplcd Co-opted Co-opted Co-opled Janiiary 2025 April 2024 Key management rexnuneration Total remuneration paid 10 key management personnel during the fjnancial year included wages and galaries amouniing to £161,792 (2023 - £193,941) and contributiong to defined contribution pension sehemes Df £10,055 (2023 - £9,073). and 5rn)Lincf<ilion of ke lana cmcnt er8aiinel Permanent staff have yearly appraisals with aims to achieve for the year and are given opporiunilies to develop themselves with training that the BPNA covers the cost towards. If siaff achieve all their objectives they will get a grade increase (between 2qo & 4%) until they reach the lop band of their pay grade. BPNA staff positions and pay are reviewed annually and are benchmarked within the recrLiiiment market and similar organisalions. RE￿ I RENCE AND ADMINISTRA TIVE DETAILS Registered Charity number 1159115 Principal address 2 Si Andrews Place Regent's Park London NWI 4LB Trustees Professor M Kirkpatrick Dr M J Griffiths Dr A McLellan Dr A Parker DrDRam Dr S Amin Dr D Lumsden Di. M Prasad (appointed May 2023) Dr S Mordekar Page 28

rltLsh Paedlatrie Neurology Assoclation Report o( the Trllstee8 for the Year Ended 31 March 2024 REFERENCE AND ADMif41STRAJIVE DEfAILS Audl¢or DonnellyBentl¢y Ltd 70 Chorl¢y New Road Bolton BLI 4BY Bankers Barclays Bank PLC 15 Bene't Street Cambridge CB2 3PZ TRUSTEES, RESPONSIBILITY STATEMENT The tru5tee8 are responsible for preparing the Report of the Trustee5 and the financial statements in accordance with applicable law and United Kingdom Ac¢ounting Standards Iunited Kingdom Generally A¢c¢pted A¢¢ounling Prnctlce) in¢luding Financial Reporting Standard 102 "The Financial Rep)rting Standard appllcable in the UK ajjd Republic of Ireland" The law applicable to charities in Englalld and Wal¢$, the Charities Act 201 l. Chatity (Ac¢oun(s and Reports) Regulations 2008 and the provisions of the trust deed requires the tsustees to prcpan financial statements for ¢a¢h financial year which give a true and foir view of the stale of affairs of the charily and of the incoming resources and appliealion of rewuw¢s, including the income and expenditure, of the charlty for that perio¢L In preparing thos¢ financial statem¢nts. lhe Itustees are required to select suitthle accounliTrg pollciBs and then apply th¢m consistently. observe the methods and pi'inciples it) the Charity SORP., make judgemen15 and estimatcs that arc r¢asonable and PTudent' sla¢¢ whether applicable accounting st&ndard8 have been followed. subject to any material departures disclosed and explain¢d in lh¢ financial statements; prepaK the financial 8tatements on the going concern b&sis unle85 it is inappropriate to presume d)al thc charlty will continue in business. The tnjstees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any tim¢ the rinan¢ial position of Éhe charity And to enable ihem to cnsurc that the financial statements ¢omply wirli ihe Charities Act 2011, the Charily (A¢¢ounts and Reports) Regulations 2008 ond the provisions of the trust deed. They are also r&S￿nSIble for safeguardiDg the assets of the charity and heJ)¢e for taking r￿￿onabLe Steps for the pr¢vention and dekction of fraud and ocher irr¢gu12riti¢S. Approved by order of the board of trustee8 on and signed on its behalf by: r S Mordekar- Trustee Pag¢ 29

Report of illo Tiideycndeiil Auditor lo the Trtsslees or Brltlsli Pacdialric Ncutology A8￿￿e1&t]0n Wc have- audiied Ihe financial .IlaleiMciil8 of Briri.Ili PaLdi&iric Neui'ology A%.iuciaiioii (Ihe 'chJriiy'l for (he year ended 31 Mareli 2024 wliiL,li eoiiipi'i8e the Srui¥inE)71 1)[ FinanLial Aclivilic¥. rlie BalancL sheci, ilic Cash blow Sid(¢ineii¢ and iintes i(1 IhL fiii4iici&l btaieinenls. inclllding a &uinniaiy of .$igi)ifi¢45I)1￿ccOu￿Ilng iialiLie%. The finuiicial i￿PortI17g framewnrk Iliat hdg b￿n appliEd in ihttii. prepai'iiiifji) 18 appliLttblv law and UniiL,d Kin&idoiii AL'Luunlin¥ Siaiiddrdi (Uniled KiiikFdum Cjttncrally Aecepled ALcounling Practice), includiiig PinanLial Re.k)orting .Siandai'd 102 'Th2 Fiiiancial Reporling Siandard upiilicttble In thc UK Kepuhlie ()[ IrelAnd'. give 8 (rue and t'gir vi¢w ot Ilie bl?Lie Df the cliariiy's tsflaii'5 a5 81 31 Marcli 2024 and of 115 IIILoming resoiiir¢s and pplication of ie%ourLeR. I'OT Ih¢ yedr ihen Lnded; hav¢ been piY)PCTly pi'epared in accoi'diince with Uiiiied Kiiig(l()In GenL'illy ALcepied AcLouTiiin¥ Pr￿ctiCe. and hav¢ b¢en ptttpared iii accnrdfiiiL'e wiLh IhL requiremenii of Ilic Cl)arilib% ACL 2011. Wc Londucied our &udir in Lccordaiice willi Iniernatioiiul Siai)dards oil Audiilng (UK) IISAS IUT<II Iiid app15¢'abl¢ law. Our 812¢emenf% xeciion of oui. I'eport. W¢ are iiidcpendEni of Ille ¢lidriiy in aLeoi'daii¢e willi Ilie eLhical ir<iuiirmeni.s ihal are r¢lev8ni to our audii of rlie finaiiciLI .%ioi¢iMent5 iii LhL UK, iiiclu(ling Llic F,'RC.'s EI111Cic I ,%lindard, aiid we liovo fulfilled nui. Iiti. EIIIiLiil I'eSFK)nbibiliiie& in ilCLtJi-dtincg wilh the￿ts I'eqklll'ements. We believe Iliai IliL diidit evid8n¢e wo liuve ()htilll)ed Culi¢lusioi￿ relallrhg lo Kolhg ctsiice111 In iudiLin¥ Ihe fii)anLial ilaLcin¢nLI, wtt liavL ¥onLliided ihai th# Iru%leLS' U%L <)[ guiiiLI LL)IlLerri bag18 of aLLOlliiLSiig iii Lhe prepar&iion uf th¥ fii)&llLial &lui#in#iiis is approprillle. BaNcd on ¢liL WOTk wc Iinve p¢i'l'oi'nicd, Ivc havc iiot idciiiilicd any ii?a(crial uiicer(aiiili&% I'clalill&) IL> LVel)i% or LOTSdiliun. that. individiiRlly nr coll¢ciivcly. Iiiay CiiSI %igiiil'l¢iinl iJoiib( un Ilie Lli4rily'S abiliiy 10 coiiiii)Iic as a going concern for Oui. re5ponsibiliiies and 1118 respuiisibilities ol. Ihe Ii'iist¢c¥ wiih respeLi [() going c011eern arc d¢bcribed in Lhc relevan( seclions iyc thL5 repoit, Oilier Infnrillatiun Tlie trusices are reai?i?Tl.%ihltt ffjr the nihoi, iiiftsriiiotion. Tli¢ oihLr inloriiiatiiin ¢oiiipriscs Ihc iiil'orination included iii ihe Slti(cd iii our iei7(JTI, we dLi Iini cxiirL%.4 iiiiy I'orni ol kl.s6uraiiLY C()IILlu,%iuii ￿l¢ll0￿. Tn coiiiieciioi) witli ODI. audil o( (hc liiiBnL'ial slalttnienis, our respi)n.sibilily [.% 10 rcad Ilic aiher iTiforrralian ai¥J. in doijg $0, eonsidor whLbrliei tfjie oiliei. infui'iiiiiLinii 1% rnaierially incoiisis￿n1 wilh Ihc finaiicial siHiemenlS oi. our knowledge obLaiiicd in Ihc audil f)I' otlierwise &ppears 10 bc nialLI'i#lly mi.%Sl#lcd. Ir we idcntify .%uch Inaicrial incoii%i%iciici¢.4 oi. appaiiiit maierial I￿ issiul¢snenis, wtt ure rcqLiired to dLierrnine ivhEilieY Il)is ¥ive,% rile 10 a mdleriol iiii55iaieintnl iii thc fiiiènLial Sta￿nien[S thcnistlves. Ir. b￿SLd an Ili¢ woik we Ii>vc PLrfLirmL,d. WL ¢()￿c1LldC 11141 IhLre is a InalLI'ial Iiiisyialemtiil of Lhis o(liei' iiif(mKtion. we r¢qi(iied ¢0 reiioi't Iliiii fklcl. We hiive Iiuihing to repori in Iliix ii'.giii'd.

Report of the Ind¢pendciit Auditfir to the Thistees of Brilisli Paedlatric Neurology As%oclAtlon Malters on wliieli we are requlred to iport by exception We have noihin¥ lo reporl 111 TespeLt of Ihe lollowiiig maiicr.% whei'c Ihe ChariLi¢s {Ac¢ounls and Reports) Regul¥tioiis 2008 reqiiiffs us io ycptsrr to you if, in oui. opiiiion= the infnrmatioii given in ihe Report of Ilie Trnstecb is inconxistent in any mdiei-ial I'Gspect with Ihc financial .%tatcments; or sufficieni accounting rocords havc not been kepi- or tlie finaneial statttmenis are n()t in agi'eelncni with die accuuniing recnrds and rellir￿. or we have nul reLeivLd all (hL inforinttiion and txplana(ions we require for vui. aLidii. Responsibilities of trustees As explained mor¢ fully in lh¢ Tru8te&%' Re8pi)nsil)ilitie% Statement, Ihe li.￿$(¢e% arc rc5POD.%ihle for the prep3ratioD of the fiiianLial starements and loi. being $ati%fi¢d that (h¢y give a irue &nd fair view, and for liucl) internal Lonirol as the trnsiees de[Cr￿)In¢ i¥ iiecebsai'y w enable (lle preparaiion of fiiiancial Staiements tliat are free froin malerial niis.%iateinent, wlieiher di1¢ to ti'aLid oi. ciyor. In pi'epariiig rli¢ financial bl4iLemeiits. the trus(¢¢5 are responsible for assessing tli¢ charity's abilily t(J continlle as a going conceni. disLlo%ing. ds applicablc, Inattcrs related ro goiiig concei'n and using dic going CDI)cern bdSit> of accounting unlc$6 the tTiislees either iiilend 10 liquidate Il)c cl)aTity or to cease operaiKons. or have no reali,sric altei'native but lo do.$0. Our responsibilities for the audll of the Iln•knclal stateinents We have been appointed a8 auditor under SeL"(ion 144 fif Ihe Chariiies Aci 2011 and repDrt in accordance with the Ae¢ and relevant regullltsons Inade or having effe¢1 th¢reuiid¢r. Our objeLLives are (o obiain veasonable a$su17nLe aboui wliL(hci' lh¢ fiiianoi81 %ialements aq & whole arL firL. froni malerial missiateni¢nt, whethei. due to fraud or errnr, and io issue an auditor's repori thai iiicludcs our opinioii. Reasonable &5burance is a high level nf assuranc¢: bu¢ ili n()t a guarantee Ili&t dn audit coiiductLd in accordai)ce with l.SAs (UK) will Rlways detec( a material niis%ia(LinttllL wlittn il e%isis. Mi58iaiemenis ¢an arise frum fralld or error and arL¥ Ly)n8idered m&tLrial ir. individually or in tile aggreuaie, (hey could reasonably be expected to influencL tl)e economic dccisions of u.sers takeii on the basis of ihe fiiiaiicial bt&teinents. Irregularitie5, iiicluding fraud, ar¢ in51anccs of non-coinplianee witli laws and Legulaiions. We design pro¢edures in line witli our I'esponsibilities. outlined above, lo detec[ material missiatemenis in r&¥peeL of irr¢gulai'i(ie¥, including fi'aud. The c%(eni 10 wliich our proccdllre5 arc capablc ol dcteciing iffcgulariiics. incliiding fraud is dctail¢d bclow.. We obtained an understanding of the legal and regulatory frainework applicable tu the cliari(y aiid the sector in whicli il QPLY'aies and Lnnsidercd ihe risk of non- compliance with ai?pltulile IdW.S oi. regiilalinns. We detennined that ilie followiiig laws aiid regulations were Inosl significant: the Charili¢s Act ?01 l and Accounting and Rei)()rtsiig hy Chariiies.. ,8iatenwnt ()f Recommended Praclice Api)licable to cliarities preiwring tlieir aCLOLlli16 in accordance wilh the PinanLial RLponing Stsndai'd appliLable in thL UK and RttpubliL of Ii'eland is.%lled in OL'¢uber 2UI g. W¢ designed audii proL'edure8 to respond to rhc risk. recognizing 11)at tlie risk of not deiec(ii)o a material misslatement dlle to fraiid is highcr Ilian thc risk ()[ lio( delec(ing one rcbultiiig froin error. 85 fraud mily involve deliberate coiicealmenl. for example, rorgery or illtcntiunal 1￿1.5repre.1tl)la(Itsns, or ihruugh Lollusii)n. We obiained an und¥i'blandiiig of how Ihe LI1￿)LY ib complyiiig will) thosv le8￿ and regulaiory fraineworks by making cnqllii-i&% of thu rnana¥cnicni. We coi'roboi'a¢ed our cnquirie.s through our rcviLw of board Ininut&%. Oiir tests also included ag￿¢11]g the financial Sfdteinenis disclo.%vreb to underlyino SUPPOTtiiig documentation. There are inhcreht limitation& in (hc dudii pi'occthirc& dcscribcd above ai)d. th¢ I'iii'lhci rcmoved noii-cornpliancc with Idws and I'egulaiion,% froni tlie events and iraii8actLOII8 reflectod in tlic financial .%iaienienLS. the less likely we wnuld become aware uf it. We did not identify aTJy key audii Matters r¢lalin8 (o irregul￿7(1¢5, incllldiiig fraud. WL al%LI ddre%fe(i ihtt ri.sk of Thaoageinenl ovenide of intwnal LQ)nirol&, inelllding lesling joui'na15 and evalualing wheiliey there was evidence of bias by the direciors tliat I'epresenled a risk of Inaierial mi8sLatemeni due 10 fraud. Page31

Report oethe tndependent Auditor to the Trustees or Britlsh PaediatrAC Neurology Association A further description of our responsibiliiie* for ilie audii of the fsnancial staieineiiL%' is located on the Finaiicial Reprjriing Council's websiitt a( www.frc.org.uklaudiiorsresponsibiliiies. This descripiion forins parl of our Repori of the Independent Audilor. Use of our report Thib Irporr 18 made solely to the chariry's Irus¢ees. a¥ & hody, in accordance wilh P&rL 4 of ihe Charitics (AcL'Dunts' and Repoi'ts) Regulation8 2IX)8. Ollr alldiL work lia% been uThderraken so iba( we mighi sta(e 10 the chariiy's Lrusrees those matte13 we requir¢d to state to ihem iii an auditor's Jtporl and for iJo otlier purpose. To rhe fullesi ¢xceDI penniLted by law. we do not ac￿p1 <Jr J&&urne responsibilily 10 dnyane oiher than the eharily and ihe charily'b lrnstees is a body. for nur audit work. foi. Ihi8 rcporL, or for (lie opinions WL have formed. D..4Ert LVJ DonnellyBeniley Ltd 70 ChorlLy N¢w Road Bolton BLI 4BY Daio: DonnellyBeniley Lid i& eligible for 4ppoiiiiment as auditor of the charity hy virtue of its trligihility for appoilllment audiror of a c(ITnpany under secuun l ?12 of the Companies Aci 2006. Page 32

British Paedlatrlc Neurology Associ8tion Statement of FinAnclal Actlvities ror the Year Ended 31 March 202A 2024 To￿1 funds 2023 Total funds Unrestricted fundg Restricted Noles INLC)ME AND FNDOWMENTS FROM Donations and legacies 150.001 261,122 411.123 255,960 Charltable gctlvities Annual confcrence Shurt courses Distance learning courses International shorL courses R¢s¢arLh Membership and professional support IPNS recharges Confcrcnccs, courses and recharges Professional support Suppon co8tS Invited Rcvicws Inveslment income 294.950 288.591 67.281 3.469 1.2tK) 117,784 294,950 2811,591 67,281 3.469 1,200 117.784 344,377 268,917 71,560 31.156 1.200 109,963 43.728 11,670 5,499 3,BlO 11,670 5,499 3,810 5.304 19,4(K) 2,841 12,388 12.388 Total 956,643 261,122 1,217,765 1,154,406 EXPENDITURE or4 Charitable activities Annual conference Short courses Distance learning courses International short courses Research Membership and professional support EPNS recharges Support costs Governance costs Invited Reviews 338.310 148,967 96.Y72 184.219 105.449 135,500 338.310 260,287 96,972 184,219 105,449 135,5(NJ 211,318 205.950 89.960 176,789 105,503 123,614 40,490 9,811 47,441 20,284 111,320 11,224 43.918 10.771 11,224 43,918 10.771 Total 1,075,330 111.320 1 186 650 1,031.160 NET INCOMEI(EXPENDITURE) Transfers between funds (118.687) {15.173) 149,802 15,173 31.115 123.246 17 Net movement in Cunds (133,860) 164,975 31,115 123,246 RECONCILIA TION OF FUNDS Tothl funds brought forward 919,562 13,076 932.638 809,392 The notes form part of these financial statement5 Page 33

British Paedlatrlc Neurology Assoclatlon Sta¢¢ment of ￿nancIAl Activities for the Ye8r Ended 31 MArch 2024 2024 Total funds 2023 Total funds Unrestricted funds Restricted funds Notes TOTAL FUNDS CARRIED FORWARD 78fj,702 178,0f1 9()3,753 93?.6.18 CONTINUING OPERATIONS All inwme and expenditure has arisen from continuing activities. RKSTRICfED INCOME AND EXPENDITURE Comparatives for income and expenditure All income and expenditure in 2023 was unrestricted apart from: Donations and legacles Income International League Against Epilepsy (ILAE) The Buist Fund- University of Dundee Jazz Pharn 65,915 20,000 12,000 Charitable 4c¢lvltles expenditure Short ¢ours¢s International short courses Annual conference Membership and professional support Research Invited Reviews Distance learning courses Governance costs 14.281 36,877 8.395 8.160 2,352 970 9,442 4.362 The notes form parl of these fjnancial sialements Pag¢ 34

Brltlsh Paedlatrlc N¢urology Asso¢i4tion Balance She¢É 31 March 2024 2024 Tota] fvnds 2023 Total funds Unrestri¢led fi]nds Restricted fuAd8 Notes FIXED ASSEYS Taugibl¢ assets 12 21.243 21.243 10.402 CURREwf ASSETS Stocks Debtors Cash at bank ond in hand 13 14 9.023 55.087 885.602 9.023 65,203 1.053,537 11,061 40,051 981135 10,116 167.935 949,712 178,051 1,127,763 1.032247 Amounfs falling du¢ within one yadr 15 1185253) (185.253) Iiio,oii) ET CURRENf ASSETS 764,459 178,051 942,510 922236 TOTAL AsS￿s LESS CURRENT LtABtLITIES 785.702 178.051 963,753 931638 NET A&8ETS 785.702 179,051 963.753 932,618 FUNDS 17 Urtrestricted funds Re$(ricted ￿lldS 785,702 178051 919562 13,076 TOTAL FUNDS 963,753 932.638 11 tu... The financial sraternents were approved by Ehe Board of T￿￿tee8 and auth0ri5ed for issue on ...................................... and were signed on its beb8]f by.. Dr S Mordekar- The notes forni part of these financial statements Page 35

BHtlgh Paedlatrle Neurology Asso¢latlon Cosh Flow Sthtemenl (or tli¢ Year Ended 31 Mgr¢h 3024 2024 2023 Noi¢s Cgsh flow8 from operntlll8 actlvliles Cash ￿n￿Oi.ed from operall￿] 711.-5118 c8¥h proylded by operating activities 78,.fi68 Coth now8 from Inveitln¥ acllvltle PurohoNe ts( Langible fixE(J Sal¢ of tangible flxed ￿$8[5 Intere6tn¥iv¢d (l8.61U) (4.LJ(}lJl ,1141 Net eaxh uBed In Inv¢8ting activities 1.1.1281. Clignge In c8¥h ewsh equlvslenls In the r¢portlTrg perlod C#6b and cAs1i equfvalents at the he￿nnIng of thoreporthig yerlod 72,402 872,fJQfi Cath 4nd ￿5h equlvglents at the end of the reportlmz perlod 1,0.53,-fj.?7 981 115 The nolES form parl of Ili2se finaiicial S￿remen[S Po¥¢ 36

Brlilsh Paediatric Neurology Association Notes to the Cash Flow Statement for the Year Ended 31 March 2024 RLCUNCILIA TION OF NET INCOMF "ro NET CASH FLOW FROM OPERATIIYG ALryIVITIES 2024 2023 Net income for the reportlng period (As per the Statement of Financial Activities) Adjustments for: Depreciation charges IA)ss on disposal of fixed assets Inieresi received Decrease in stocks Increase in debtors Increasel(decrease) in creditors 31.115 123,246 7,081 652 (12,388) 2,038 125,152) 75,242 3,470 {2,841} 4,623 (3,118) (13,812) Net cash provided by operations 78,588 111.568 ANALYStS OF CHANGES IN NET FUNDS At 114123 Cash flow At 3113124 Net ea5h Cash at bank and in hand 981,135 72,402 1,053,537 981,135 72,402 ,053,537 Total 981.135 72.402 ,053,537 The notes form part of these financial statements Page 37

British Paediatric Neurology Assoeiation Notes to the Financial Slatements for the Year Ended 31 Mgreh 2024 STATirroRY INFORMATION British Paediatric Neurology Associalion is a charitable incorporated organisation registered with the Charity Commission for England and Wales. The registered charity number number is 1159115 and the principal address is 2 St Andrews Place, Regents Park, London, NWI 4LB. The charitable incorporated organisation constiluies a PLiblic benefit entity as defined by FRS 102. The presentation currency of the finE￿¢￿al 8taiemenis is the Pound Sterling (£). ACCOUNTING POLICIES Basis of preparing the fin&nci41 statements The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accour]ting and Reporting by Charities: Siaiemenl of Recommended Practice applicable lo charities prepai'ing their accounis in accordance with the Financial Repor(ing Standard applicable in the UK and Republic of Ireland (FRS 102) (effective l January 20191,, Financial Reporting Standard 102 'The Financial Reporting Siandard applicable in the UK and Republic of Ireland, and the Charities Act 201 l. The financial slalemenls have been prepared linder the historical cost convention. Going concern The Trustees have assessed wheiher the iise of the going concern basis is appropriate and have considered possible events or conditions that might cast significant doubt on the abiliiy of the charity to continue as a going concem. The Iruslees have made this assessmeni for a period of at least one year from the date of approval of the financial siatements. In particular the trustees have considered the charities forecasts and projeciions and have taken aCCOLint of pressLires on income. After making enquiries ihe iruslees have concluded thai there is a reasonable expectation that the Charity has adeqLlate re8ources to coniinue in operation1< l eXiS￿nCe for the foreseeable fLilure. As such ihe charity can expect lo be able to meet ils liabilities as they fall due in the period of al least 12 monlhs from the dale of approval of these accounts. However, there can be no certainty in relation to these matters. On this basis the Trustees have concluded that the charity is a going concern. The financial statements do not include any adjustments that would resiilt from the charity noi being able lo meet ils liabilities as they fall due. Income All income is recognised in the Statement of Financial A¢tivilies once the charity has enliilement to the funds, it is probable that the income will be received and the amolinl can be measured reliably. Income from grants and donatlons Donaiions and grants are recognised when they have been commiini¢aled and received in writing with notificaiion of both tFLe amount and settlement da￿. In the evenl tha( a donation or grant is subject to conditions ihal requii'e level of performance before the charity is entitled to the funds, the income is defei-red and not recognised until either those conditions are fully met. or the fulfilment of those conditions is wholly within the control of the charity and it is probable that those conditions will be fulfilled in the reporting period. Ineome from membership subserlptions Membership subseriplions are initially recognised in the period that the member pays the subscription ￿ the charity. Membership SLibscriplions received in the year relating to the period after the reporiing date are re¢ognised as deferred income. Income from sponsorship ggreements Page 38 coniinued..

British Paediatric Neurology Association Notes to the Flnanclal Statements - continued for the Year Ended 31 March 2024 AccouwfING POLICIES - eontinued Income Sponsorship income is initially recognised when invoiced in line with the terms of the sponsorship agreement. Income received or invoiced in the year relating to the period after the reporting date are recognised as deferred income. Income from conferences Income in relalion lo conlercnccs is inilially recognibcd in thc period in which the atlendee pays Ihe allendance fee. Income received for conferences taking place after Ihe rcwrling date are recogni.4ed as deferred income. Income Crom courses Income in rclation to courses is initi<illy recognised at the point which the attendee has booked and paid for iheir attendance on the coursc. Incom¢ received for courses laking place after the rcporling dale are recognised a5 deferred incotne. Income from EPNS recharges Income in relation lo EPNS recharges is initially recognised ai the point which the EPNS is invoiced for the costs incurred by BPNA. Inconie not invoiced a5 at the reporting date is recognised as accrued income within the fJnan¢ial statements. Expenditure Liabilities are recognised as expenditure as soon as there is a legal or conslruclive obligation committing the charity to Ihat expenditure, it is probable that a Iransfer of economic benefils will be required in settlement and the amount of ihe obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated lo a¢livities on a basis consisienl with the use of resources. Grants offered subject lo conditions which have not been met at the balance sheei dak are noled as a commitment bul not accrued as.expendilure. Tangible fixed a55ets Deprelialiun is pruvided ai the following annual raies in order to Wri￿ off each asset over its estimaled useful life. Plant and machinrry Fixturcs and fillings 25% on rcducing balance 25% on rcducing balance The tangiblc fixed assels of the charity are reviewed by the charity's executive director and ihe trustees for impairmenl on a regular basis and during the preparation of the financial staiemcnls. Stock5 Siocks are valued at the lowcr uf cobi and Det rcalisablc valuc, aficr making due allowancc foi obbolele and slow moving ilem8. Taxation The chariiy is exempl from lax on ils charitable activitie5. Fund accounting Unrestricted funds can be used in accordance with the charitable objectives al the discretion of Ihe Irustees. Restricted fund5 can only be used for particular restricted purposes wiLhin the objects of the charity. Re51riclions arise when specified by the donor or when funds are raised for particular restricted purposes. Page 39 continued...

Bri¢ish Paediatrlc Neurology Assoelation No¢es to the FI￿ncial Statements - continued for the Year Ended 31 Mareh 2024 ACCOUNTING POLICIES - contlnued Fund accountlng Further explanation of the naiure and purpose of each fund is included in the noies to ihe financial slaiements. Debtors and credltors receivable I payable within one year Debtors and creditors with no stated ini¢rest rate and receivable I payable within one year are recorded at transaciion price. Any losses arising from impairment are recognised in expenditure. Forelgn eurrencies Asseis and liabilities in foreign currencies are translated into sterling at the rates of ex¢hange ruling at the balance sheet date. Transaciioiis in foreign ¢iirrencies are translated inio sterling at the rale of exchange ruling at ihe dale of transaction. Exchange differences are taken into account in arriving at the operating result. Pension costs and other post-retirement benefits The cliarity operates a defined contribution pension scheme. Contribuiions payable to the charity's pension scheme are charged lo the Statement of Financial Activities in the period to which they relate. Flnoncial instruments A financial assei or a financial liability is recognised only when the eniily becomes a pariy lo the conlraclual provisions of the insiruments. Basic financial instruments are initially recognised ai the transaction price, unless the arrangemenl constitutes. in effect, a financing transaction, where il is recognised at the present value of the future paymenis digcoiinled al a market rate of interesi for a similar debi iustrument. Debt instrumenis are subsequently measured at amortlsed cosi. Other financial instruments are initially recognised at fair value, unless payment for an asset is deferred beyond normal business tern)s or financed at a rale of interest thal is not a market rate, in which case Ihe asset is measured al Ihe pi'esenl value of the future payments discounted at a market rate of inleresi for a similar debi instrument. Financial assets that are measured at cost or amortised cost are reviewed for objecrive evidence of impairment at the end of each r¢porting date. If there is objective evidence of impairment, an impairmeni loss is recognised in profit or loss immediately. Any reversals of impairnieni are recognised in profit or loss immediately, io the extent that the reversal does not result in a carrying amounl of ihe financial asset ihat exceeds what the carrying amount would have been had the impairmeni not previously been recognised. Page 40 conlinued.-

British Paediatric Neurology Assoel8tlon Notes to the Flnanclal Statements - continued for the Year Ended 31 March 2024 CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY The preparation of the financial statements requires managemenl to make judgements, estimates and assumptions thai affect ihe amouiits reported for asset5 and liabilities as at the balance sheet date and the amounts reported for revenues and expenses during the year. The nature of estimation means that actual outcomes may however differ from ihose original eslimales. The trustees do not deem there to be any judgements. apart from those otherwise disclosed in the accounting policies or notes to the financial stalemenls, which require highlighting to the readers as a result of having had a Critical effeLI on amounts reeognised in the financial slalemenls. DONATIONS AND LEGACIES 2024 2023 Donations GranLs Gift aid Membership donalinns Annual cnnferencL Sponsorship Short course sponsorship Trainee Sponsorship Misccllancous income 23,660 242,718 5.245 120,415 1.063 1,950 90.0(K) 25,5 11,200 110.500 14,750 7,500 795 .787 411 123 255,960 Grant5 received, included in the above, are as follows- 2024 2023 Inlernaiional League Against Epilepsy (ILAE) Department for International Development (DFID) via the Tropical Health and Education TrL151 (THET) Pet Grant Movement di50rder income The Buist Fund- University of Dundee GW l Ja7.7. Pharma BAND & RUW Foundations Grant 54,878 156,300 65,915 5,(M)O 15.000 7,500 2O,OUO 12,OLK) 26.540 242,718 120,415 Page41 continued...

Bri¢ish Pv4ediatric Neurology As80¢iation Notes to the Fhnanelal Statements . contlnued for the Year Ended 31 March 2024 Sponsorships received, included in the above, are as follows: Conference sponsorshlp Course sponsorship 2024 Tota18 2023 Totals Company name Alexion BioGodex Biogcn D¢silin Egetis GWlJaLz Pharnia Neuraxphami UK Immedica Novartis Nutricia Orchard Orion Pharnia Proveca prc Roche Sarepia UCB Pharma Veriton Vitaflo 6,0 7,5(K) 7.5(Kl 6.0(K) 6,OtM) 6,000 7,500 7.5(M) 19,750 6,0(Y) 9.0(M) 6.0(K) 20,5(K> 6.(K)O 13.750 9,000 6,0 6,000 2,000 7.500 6.000 7,5 6.000 2,000 7500 6,000 7,500 6,0 6,0 6,0 6,0(K) 2.0(K) 6,0(M) 7,500 7,500 13,5(K) 6.000 6.(K)O 2,0 6,0 8,5CH) 7.5tK) 13,5(K) 6,(M)O 6.LK)O I,(K)O 8,(X)O 9.(M)O 6.(K)O To¢al Sponsorship 110,500 14,750 125,250 115,500 Pag¢ 42 continued...

British P8ediatric Neurology Association Notes to the Financial Statements . contlnued for the Year Ended 31 March 2024 INVESTMENT INCOME 2024 2023 Deposit account interest 12.388 2,841 INCOME FROM CHARITABLE ACTIVITIES Distance learning cour5CS Annual conference Shor( courses Annual confeicnce Short courqes Intemational short courses Distance learning EPNS rechargeb BPNSU fee income Invited Reviews Trainee Fees BPNA membership subscriptions Annual conference symposium sponsorship External room hire 228.950 288,591 67,281 66,000 294,950 288,591 67,281 Page 43 continued...

British Paediatric Neurology Associatlon Notes ¢0 the Financlal Sts¢ements- COn￿￿lled for the Year Ended 31 March 2024 INCOME FROM CHARITABLE ACTivrrIES - continued Membership Conferences, courses and recharges International short courses professional support Research Annual conference Short courses International short courses Distance learning EPNS reCh￿geS BPNSU fee income IDVited Reviews Trainee Fees BPNA membership subscriptions Annual wnference symposium sponsorship Bxlernal r(K)m hire 11,670 3.469 1,200 117,784 3,469 1,2(X) 117.784 11,670 2024 Total activi¢ies 2023 Total activities Professional support Support ¢osls Annual conference Short courses Inlernalional short courses Distance learning EPNS recharges BPNSU fee Income Invited Reviews Train¢¢ Fees BPNA membership subscriptions Annual conference symposium sponsorship ExlernaI room hire 2,460 243,080 288,591 3,469 67.281 278.377 268,917 31,156 71,560 43,728 1,2(Kl 19,4(K) 5,304 109,963 66,000 1,2(X) 5,499 5,499 117,784 66,(KJO 350 1,3.50 7()4,254 8().5.605 Page 44 coniinued...

Brltish Paediatric Neurology Association Notes to the FiJJancio1 Statements - continued for the Yegr Ended 31 March 2024 Sponsorships received. included in the above, are as follow5- Symposia sponsorship 2024 Totals 2023 Totals Company name Biocodex Biogen Desiiin GWlJazz Pharma LTF Pharnia Novartis Frc Roche UCB Pharma Total Sponsorshlp I 1,000 11,000 LI,￿0 I l.O(K) I I,O(K) I I,O(K) I 1,000 11.000 I 1,000 I 1,000 I I.OQK) I i.o(K) I I.ooM) I I,o(K) I I,(K)O I i.(M)o 66,000 i i,o(x) i i.o(MJ 66,000 66,000 CHARITABLE ACTIVITIES COSTS Grant Grant funding of aclivities (see note 81 Support costs (see note 9) Direct Costs Totals Annual conference Short courses Distance learning courses Inlernaiional short courses Research Membership and professional support Support costs Governance costs Inviled Reviews 240,731 110,4(K) 30,548 59,885 4,034 76,786 11.224 97.579 149,887 66,424 124,334 18,446 58,714 338,310 260,287 96,972 184,219 105,449 135,5(K) 1.224 43.918 10,771 82,969 43,918 10,771 533,608 82.969 570,073 1,186.650 Page 45 continued...

Britlsh Paedlatrlc Neurology Assocl8tJon Notes to the Financial Statements- Continued for the Year Ended 31 March 202A GRANTS PAYABLE 2024 2023 Research The total grants paid to institutions during the year wa$ as follows: 2024 2023 Year l of 3 joint research training fellowship with Action Medical Research Year 2 of 3 joint research training fellowship with Action Medical Research Year 3 of 3 joint research training fellowship with Action Medical R￿arCh 41.667 41.302 41.667 41.302 82.y6() Page 46 ontinued...

Brittsh Paediatric Neurology Association Notes to the Financial Statements . conlinued for the Year Ended 31 March 2024 SUPPORT COSTS Infomation technology Human resources Finance Annual conference Short courses Distance learning courses Intemalionul %horl courses Research Membership and profc$￿ional sllPPOrt Governance co81 Invited reviews 113 174 78 145 22 69 38 4,423 6,796 3.1112 5.637 836 2,662 1,458 488 73.767 13,314 50,219 93,997 13.946 44,387 24,309 8,142 652 25.312 422,081 Governance cost5 Other Totals Annual conference Shorl courses Distance learning courses Intemational short cour5e5 Research Membership and professional sUPPOrt Governance cosls Invited reviews 18,540 28,474 12.615 23,619 3,504 11,154 6,108 2,047 736 1,129 500 936 138 442 12,005 81 97,579 149,887 66,424 124,334 18,H6 58,714 43.918 10,771 106,061 570 073 Support costs, included in the above, are as follows.. Distance learning courses International short COLifscs Annual conlLrLnLe Short courses Research TrustCCs' remuneration elc Loys on sale of tangible rixed dsscls Safiware subscription Computer repairs Wcb5ilc h05ting Website development Computer upgrade Dcpreciation of tangible fixed assets Employmenl costs Social security Pensions 113 1.651 259 95 1,157 51 174 2,536 399 145 1,779 76 78 1.124 177 64 788 34 145 2,104 331 120 1.475 63 22 312 49 18 219 1,210 61,803 5.223 3,679 ,861 94,934 8,024 5,651 825 42,073 3,556 2,505 1,544 78,750 229 11,684 987 696 4,689 Carried forward 75,241 115.579 51.224 95,877 14,2 Page 47 continued...

British Paediatric Neurology Association Notes to the Flnand&l Ststenients- contlnued for the Year Ended 31 Mareh 2024 SUPPORT COSTS - continued Distance earning courses International short ¢ourses Annual conferenc¢ Short courses Research Br()ugh¢ fonvard Sthff costs Staff trnining & Welfare Recmitment costs Business rates Gas and electric Telephone Office insurance Data protection costs Health and safely ￿sts Legal fees .Marketing O￿lCe repairs and renewals Photocopier Postag¢ PrAnting and sialionery Credit card charges Bank charges Bad debi Refuse and cleaning Computer and internet Staff welfare Copyright lic¢nce London r¢nl Bolton rent Meeting costs Professional fees Depreciation of tangible fixed assets Audilors, remuneration Ac¢ounlan¢y and legal fees 75.241 396 2,314 352 35 42 713 400 42 115,579 609 3,554 542 52 51,224 270 1.575 240 23 29 485 272 28 95.877 505 2,948 449 43 55 908 510 53 14.225 75 437 67 1,095 615 64 135 76 744 2,919 107 23 ,l42 4,483 163 35 506 1,987 72 15 947 3,719 135 28 141 552 20 167 1,568 179 256 2.406 276 118) 13 242 1,357 196 10,071 2,700 585 2,633 113 1,066 122 (8) 212 1.996 229 (15) 31 296 34 (2) 157 883 127 6.556 1.758 382 1,714 107 201 1.126 163 8.354 2.239 486 2,184 30 167 24 1.239 332 72 324 87 4.463 1,196 259 1,167 26 315 421 40 483 646 18 214 286 33 401 535 59 79 97,579 149.887 124.-334 18.44C) Page 48 niinued...

British Paediatrlc Neurology Association Notes ¢0 the Financial Sta¢ements- continued ror the Year Ended 31 March 2024 SUPPORT COSTS - continued 2024 2023 Membership and profcssional siipport Governance costs Invited Rcvicws Total activities Total activities Trustees, remuneration etc Iffjs5 on sale of iangible fixed assets Software %ub8cription5 Computer repairs Wcbsite hosting Website developmcnt Compulcr upgrades Depre¢i8tion of tsngible fixed aqsets Bmploymenl cos15 Social security Pensions Staff costs Staff training & welfare Recruitmenl costs Businegs rates Gas and electric Telephone Office insurance Data protection costs Health and safety costs Legal fees Marketing Office repairs and renewals Photocopier Poslagc Printing and slatiunery Credit card Charges Bank charges Bud dcbt Rcfusc and cleaning Computer and inlerncl Staff welfare Copyright liccnce London rcnl Bolton rcnt Meeting Costs Profes.8ional fees Depreciation of langible rixed assels 8,122 69 99_3 156 57 697 30 38 544 86 31 382 16 13 182 29 10 128 652 9.446 1,486 540 6.625 284 7,416 712 576 2,400 729 37,187 3,143 2,214 239 1,392 212 21 26 429 399 20,366 1,721 1,213 131 762 134 6.821 577 406 6.931 353,618 29,887 21.053 2.269 13.237 2.017 195 245 4,079 2,290 239 3.261 302.331 27,275 15,155 11,170 1,183 9,873 374 255 39 14 235 132 14 79 5,197 1,279 239 25 M7 1.756 64 13 245 962 35 82 322 12 4,254 16,700 608 127 3,161 3,521 (125) 115 395 940 10.604 955 157 100 943 108 (7) 55 516 59 (4) 18 173 20 952 8.964 1,027 {66) 48 901 5,055 730 37,512 10,055 2.181 9,807 95 532 77 3,945 ,057 229 1,031 52 291 42 2,160 579 126 565 17 98 14 724 194 42 189 730 40,638 9,0(K) 16 150 Carried forward 58,272 31,913 10,690 554,106 466,863 Page 49 continued..

Brilish Paediatric Neurology As50Cj4tion Notes to th¢ Financial Statements - contlnued for the Year Ended 31 March 2024 SUPPORT COSTS - continued 2024 2023 Membership and professional suppon Governance costs Invited Reviews Total activities Total activities Brought forward Auditors, remuncration Accountancy and legal fees 58,272 189 253 31,913 9,104 2.901 10,690 35 46 554,106 10,800 5,167 466,863 9,(K)O 8,369 58,714 43.918 10,771 570,073 484,232 io. TRUSTEES. REMUNERA TION AND BENEFITS 2024 2023 Truslees, salaries Trustees, social security Trustees, pension contributions to money purchase schemes 7.672 239 211 8.122 Included in the remuneration paid to Ihe trustees in the prior year were amounts paid to Dr L Hartley for services rendered in relation to the development and provision of distance learning courses. Trustees, expenses Within the expenses noted above are expenses paid to the following trustees in respect of dire¢1 charitable activily costs i.e. travel expenses Leaching a( UK andlor International courses, und¢rtaken on behalf of Ihe charity in the year: 2024 2023 Dr L Hartley Dr S Jayaw2nl Prof M KirkpatriLk Dr A Parker Dr A McLcllan Dr M Griffiths Dr D Lumsden Dr S Mordekar DrDRam Dr S Amin Dr M Prasad Dr M Chitre 2.681 416 IU,719 483 45 427 195 139 164 649 14,153 564 4,425 636 658 709 1,623 720 149 23,637 15,918 During the year. in addition to the above. amounls tothlling £4,434 (2023 £5,264) related io executive tneeiing expenses that were paid on behalf of all trusiees. Page 50 continued..

Brliish Paediatrie Neurology Associatio Iyotes to the Financial Statements- continued for the Ye*r Ended 31 March 2024 ii. STAFF COSTS 2024 2023 Wages and salaries Social security cosis Pension schemes 356,738 29,887 21,053 345,432 30,948 16,993 Total 407,678 393,373 Included within creditors as ai the reporting date is £nil (2023 £3.200) in relation Lo unpaid pension conlribulions. The average monthly number of employees during the y&qr w&$ as follows.. 2024 2023 Management Support btaff The number of employees receiving gross remuneralion, inclusive of Ihe value of benefits-in-kind, greater than £60,000 per annum and lo whom retirement benefits are a¢¢ruing under defined contribution pension schemes were.. 2024 2023 £60,(X)0 - £70,OtK) Total employees Total remuneration paid lo key management personnel during the financial year included wages and salaries amounting lo £161,792 (2023 - £193,941) and contributions io defined contribution pension schemes of £10.055 (2023- £9,073). Page51 continued..

Brltlsh Paediatric Neurology Association Notes ¢0 the Flnanclal Statements . conUnued for the Year Ended 31 March 2024 12. TANGIBLE FIXED ASSETS Fixtures and fittings Plant and machinery Totals COST Al l April 2023 Additions Disposals 32,696 18.610 5,947) 3.321 36,017 18,610 6,21L) (2()41 At 31 March 2024 45,359 3,O.57 48,416 DEPRECIATION At l April 2023 Charge for year Eliminated on disposal 22,926 6,931 2,689 150 25,615 7,081 At 31 March 2024 24,566 2,607 27.173 NET BOOK VALUE At 31 Ma￿h 2024 20,793 450 21.243 At 31 March 2023 632 13. STOCKS 2024 2023 Stocks 9,023 11.061 14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR 2024 2023 Trade d¢btors Prepayments and accrued income 21,660 43.543 32,977 7,074 65.203 40.051 Page 52 Continued...

British Paedlatrlc Neurology Association Note5 to the Financiol Statements- continued for th¢ Year Ended 31 March 2024 15. CREDITORS: AMOUNTS FALLING DUE WJTHIN ONE YEAR 2024 2023 Trade creditors Social security and other taxes Other creditors Defeffed income Accrued expenses 59,830 I4.￿2 154 84,301 26.966 26,472 11.904 3,354 43,761 24,520 185.253 110.011 The deft￿cd inL()mc balance above includes income relating to traiuing courses amounting trj £84,171 (2023 £43,631) and membership subscriptions received in advance amounting to £130 (2023 - £130). 16. LEASING AGREEMENTS Minimum lease payments under non-cancellable operating leases fall due as follows.. 2024 2023 Within one year Between one and five years 16,534 3,578 11,628 20.112 11,628 During the ye&r the charity incurred expenditure under cancellable and non-cancellable operating lease agreements relating lo office rental amounting to £47,567 {2023 - £49,638). Page 53 continu¢d...

British Paedlatrlc Neurology Assoclatlon Notes to the Flnanclal Statements . conthiued for the Year Ended 31 March 2024 17. MOVEMENT IN FUM)S Net movement in funds Transfers between funds At 3113124 At 114123 Unrestrieted fun(Lq General fund Contin8¢n¢y furtd Research training fellowship fund Fetal neurology course development International faculty education fund Kenya fellowship travel fund Fellow travel bursary fund Dlslance learning development fund PET updafr course development PET hot topics course development Impact & evaluation consultancy Movement disorders course development PET 213 international update International face to face launch Website upgrade 348,574 180,0(K) 179.648 10.730 10,195 15.462 (200,606) 70,000 163,430 250,(KX) 96,679 10.448 (82,969) (282) (10,195) I,O(M) 7.125 67.825 25,143 17.600 50.(KiO 21,722 (7,125) (12,680) (18.418) (7,858) (1.000) (1,119) (9,823) 55.145 (6,725) (9,742} 49.0(K) {20,603) 9,823 60,000 ioo,(K)o l(K).( 919,562 (118,687) (15,173) 785,702 Restricted funds THET grant fund Colombia launch Zambia launch In¢ern￿lOnaI faculty education & fellow travel bursary fund 149,261 (10,929) 11,470 149.261 13.076 (2,147) 11.470 17.3?11 13.076 149.802 178.051 TOTAL FUNDS 932,638 31,115 963.753 Page 54 continued...

British Pgedlatrie Neurology Assoeiation Notes to the Financlal Ststements - continued for the Yegr Ended 31 March 2024 17. MOVEMENT IN FUNDS - eontinued Net movement in funds, included in Ihe above are a5 follows: Incoming resources Resources expended Movement in funds Unrestricted funds General fund Research training fellowship fund Fetal neurology course development Disiance learning development fund PET update course developmeni PET hot topics course development Impact & evaluation consultancy Movement disorders course development PET 213 international update 956,￿3 1941,181) (82.969) (282) (12.680) (18,418) (7,858) (1,000) (1,119) 15,462 (82,969) (282) (12,680) (18,418) (7,858) (I,(MM)) (1,119) 956,643 (1,075,330) (118,687) Restricted funds ILAE grant fund THET grant fund Colombia launch Zambia launch 54,877 159,504 (3,204) 49,945 (54,877) (10,2431 (7,725) 38,475) 149,261 {10,9291 11.470 261,122 (111,320 149.802 TOTAL FUNDS 1 ?17.765 11.186,650) 31.115 Page 55 nlinued...

Brltlsh Paedla¢rlc Neurology Assoclatlon Notes to the Flnanclal Statements- continued for the Year Ended 31 Marth 2024 17. MOVEMENT IN FUNDS - continued Comparatlves for movement in funds Nel movement in funds Transfers between funds At 3113f23 At lJ4122 Unrestricted funds GenCr￿ fund Conlingency fund Research training fellowship fund Priority setting project Fetal ncurology course development International faculty education fund Kenya fellowship travel fund Fellow travel bursary fund Distance learning development fund PET update course development PET hot topics course development Impact & evaluation consultancy Movement disorder8 course development PETI Anternational update 271,694 180,000 153.604 9.739 12,130 5,6LK) l.O(K) 6.325 76.7(X) 30.0(X) 12,6(X) 50,0(X) 99.288 (22,408) 348.574 180.(K)O 179.648 26,044 (2,206) (1,400) 895 (7.533) 10,730 10.195 3,700 800 (8,875) (4,857} 5.IX)O 7.125 67.825 25.143 17.6(X) 50,0(X) 21.722 5,222 (9.741) 16.500 9,741 809.392 110,170 919.562 Restrlcted funds Colombia launch 13,076 13.076 TOTAL FUNDS 809,392 123,246 .3?,()38 Page 56 continued.

British Paedlatrlc Neurology Association r4otes ¢0 the Financial Statements- continued for the Year Ended 31 March 2024 17. MOVEMENT IN FUNDS- continued Comparative nel movement in funds, included in the above are as follows: Incoming resoiirces Resources expended MoveTnenL in funds Unrestrieted funds General fund Research training fellowship fund Priority setting project Fctal neurology cour.ge devclopment Internalional faculty cducation fund rellow travel bursary fund Distance learning dcvclopment fund PET updalc Lourse development PET hol topics course developmcnt Movcmettt disorder.q coursc dcyelopmenl PE'I'I inlcrnaiiunal update 891,632 109,013 1792,344) (82,969) (2.206) (1,4(X)) 99,288 26,044 (2,2￿) (1,4(X)) 895 8(K) (8,875) (4.857) 5,000 5,222 (9,741) 895 800 400 11,250 5,000 7,500 30,IM)I (9.275) (16,107) (2,278) (39.742) 1,056,491 (946.321) 110,170 Restrieted funds ILAE grant fund Colombia launch 58,791 39.124 (58,791) (2C).n48) 11 (176 97.915 184.839) 13,1176 TOTAL FUNDS 1,154,4116 11.031.101)) 113,246 Coi)lin I'und The contingency fiind is held io suppoi't the staffing cost of running the BPNA Secretariat for a period of approximately Six months (2023 - six rnonths} should there be any contingency that might lead to a significant rediiction in BPNA operational activities, this equates to £250,0(K) (2023 - £180,CK)o). Dislancc Icai'nin devLI() mcllt liind 1.he dislancc learning dev¥lopmeni fund is a designated fund sel up by the trustees in order to preserve the aniieipated level of funding incurred for distance learning course development in the foreseeable future. This funding is provided from transfers from the general fund and includ¢s costs towards a Moodl¢ provider. Felal Neuinlii. Coiiise Develo The Fetal Neurvlogy course developmenl fund is a de.qignated fund 5Ct up by the Tru8lees lo fund development of course designed lo improve training for anyone involved in curing and coun.selling a family whose tetus ha8 a neurological abnvtmality. This funding i% provided fmm transfers from thc general fund. Page 57 Colllinued...

British Paediatrie Neurology Associution Notes to the Flnanelgl Statements - continued ror the Year Ended 31 March 2024 17. MOVEMENT IN FUNDS - eonlinued InlLI'li'ili()Ii'il Lt'd ILAE ranl fiind Thc BPNA and ILAE share a comtnilmcnt to improving care for childrcn with epilepsy. In 2005, the BPNA dcvclopcd Paediatric Epilepsy Training (PED courses lo Irain hcalthcare worker$ 10 bctlcr diagnose and treal children with seizures. PETI 15 now attended by almo%t cvciy paediatrician in the UK and thc COLwses have alNu been Idunched ovcr4cas, sctting a gold %tandard for cpilcpsy care ai'ound ihE world. Ouiside of the UK. Ihc programme currenily runs in.. Bra7.il, Ghana. India. Kenya. Mydnmar, Ncw ZEaland. South AfriLa, Sudan, Tanzania and Uganda. PET a]igns With the ILAE'S Edu¢ation Council's aim lo lea¢h competency in the diagnosis and clinical management of epilepsy. with a focus on non-5pecialists i.e. paedialricians. It forms part of the portfolio of ediicational aciivities that the ILAE aims to develop. It also supports Goal 2 of Ihe LLAE'S Sti'ategy 2030.. Support health professionals worldwide lo enhance their knowledge and skills in the prevention, diagnosis, Irealment and care of epilepsy. The BPNA aiid the ILAE first signed a pai'lnership agreement in 2018, Committing to bLiild on the success of the Paediairic Epilepsy Training courses developed by the BPNA. The ILAE has agreed to ¢over 40% of staff cogis in tlie BPNA'S Inlernaiional EdLication leani 13 staff memberg) from April 2022 10 March 2026. This equates to a total of $278,844 over that time. Fellow%lii Fiiiid ThL Re&L￿¢h Training Fellowship funds iraii)ee clinicians to compleie a rese￿ch degree (eg PhD) in ihe field of clinical neurology andlor neuroscience, including neurodisabiliiy and neurodevelopment. Fellowship applicaiils are pre-docloral trainee clinicians who either alrcady liold a UK or Irish 4peLialist trdining post in Paediairic Neiirology 01 arc planning to apply for a SPCLidlis1 tsaining post in Paedi<itriL Neurology or Neurodisubilily aftcr completion of their PhD. Both the pri)posed appliLcilion and fellowghip applicant must meet the BPNA chdl'itable aims. Income to this fund is froTn men)bers' donalions and thc income from spotLsoi¢d 5yn]posia at the BPNA annual conference. Since 2015, Ihc BPNA has partnered with Action Medical Re.%carch to fund a joini Research Ti'aiDing Fellowship award. Applicatinn.% for Ehis joint award arc considered in open ¢OTnpctition through Ihe Action Mcdical Research peer review sy51cm. Wehsile lJ I'ade Thc BPNA intends lo update their website. Thi.s fund was sei up by the Trustees to ¢over the initial cost of research and part development of the website. Inicmalion<il I'dce Eo 141¢¢ l.Aunch fund Tliis is a dc5ignated fund set up by the Trustee5 to support fullire face to face international launches that may not cover all the costs to adminisler a launch in a new couniry up Linlil March 2026. So far this fund has not needed io be ulilised Page58 coniinued..,

British Paediatric Neurology Association Notes lo the Financlal Statements . contlnued for the Year Ended 31 March 2024 17. MOVEMENT IN FUNDS - continued InlcrnationLEI Paculi F.diicaiioii Fund To enable low and middle income country (LMIC) BPNA course faculty lo benefit from BPNA educalion by funding registration fees. The aim is to support faculty to pay (or courses that Ihey would otherwise be unable EO afford. BPNA Education includes.. face-io-face courses and confei'ences held in the UK. wiriual courses or conferences and enrolmenl on distance learning units. It does nol fund travel or accommodation. Ken ,1 Travel P¥ll(Iw%hi Fiind In 2019. the BPNA and Kenyan Paedialric Association established a fellowship for UK pa¢diatric neurologists to go to work in Kenya for a short period. The KPA will pay the UK clinician's salary. This fund is lo cover the cost of their return travel expenses. PETI Dcvel PETI was lasi updated in January 2018. This money will fund the bringing iogeiher of an inlernalional development team to update PETI course materials lo reflect feedback, updates in research and guidance. PET 4w<ll'd Louf%L dLvcIo To fund developmcnt OF a n¢w coiirse designed for Ihose who attended PET2 and 3 more than 3-years ago. lil & Evci1111c tioii O(fiLCI' The BPNA hab bccn running courses Since 2005. Thi.8 money has been aimed lo fund an Impacl and Evaluation Officer to reporl on the full impacl of BPNA courses. Parl of that fund has been used lo pay for Consuliants from a Universiiy io review impact & evaluation. M()vc.mciii Disoi'dei'% Lniif%L develo Iiienl MOVED MOVED is a 2-day course being developed by Consuliani Paedi&tri¢ Neurologists and Paediatricians in Neurodisability. It will run as a siand alone course, but will develop themes from the Approaching Children's Tone (ACT) course. This course aims to cover a broad spectrum of movement disorders that are seen in children and will place emphasls on description, diagnosis and initial management of these conditions. Columbi2 Launch Fund In partnership with the Univer51ty of Antioquia and ASCONI, the Colombian Child Neurology Sociely, BPNA launched PETI in Colombia in August 2022. The Buisi Fund - University of Dundee, ILAE South America Region and Jazz Pharma¢eulicals have contributed to the Columbia Launch Fund. rant ILind The BPNA were awarded a large Tropical Healih & Education Trust ITHET) grant. Using the eslablished partnerships with the Paediatric Society of Ghana and East African Child Neurology Association in Kenya, the BPNA a￿ delivering one-day PET Course in those countries. The aim is lo increase the nutnber of country volunteer trainers, widen the geographical reach within those countries and carefully evaluate changes in practice of the parlicipanls. The grant started in February 2023 and will end in February 2024. Zambia Fund The BPNA launched PETI in Zambia wilh delegates also coming from Zimbabwe. The Launch was supported by BAND Foundation and the ILAE Africa Region. Page 59 ¢onlinued...

British Paedlatrlc Neurology Association Notes to the Financial Statements . continued for the Year Ended 31 March 2024 17. MOVEMEN'f UND.S . continued Transfers between funds The transfers between designated funds and ihe general fund have been undertaken in ord¢r lo ensure a suitable level of reserves has been designated as at ihe reporting date for Ihe purposes of the funds listed. During the year, there was a transfer froJn the Colombia Launch restricted fund to the General fund of £2,147 (2023 £124 from General fund to Colombia Launch restri¢led fund). 18. CONTINGENT LIABILITY During the year to 31 March 2024, the chariiy has become aware that cei'tain areas of ils sponsotship income are eligible for VAT. The charity has exceeded ilie V AT registration threshold, and as a result, is liable for V AT on this income in the current and prior years. The final amoiint of the VAT liability is siill being considered. It is noi possible ai ihis stagc to quantify the liability as ihe charity is yet lo confirm the levLI of iaxable income arising Imm non-UK based customers or to lh¢ Lxtcnt to which the charity may bL rciTnburscd by cu.stomer.8. How¥vcr, thc fi'inal V Al, liabilily is nut cxpecicd to exceed £112,0(X). 19. RFLATED PARTY DISCLOSURES Thcrc wcrc no related party tran8aclions for thc ycar cnded 31 March 2024 12023 - £1.973 of payments wer¥ nIt￿C lo HMLH Con.8uliing i.td loi" thc provision of distance learniT)g Lourscs. of which Di. L Hartley was diitclor and also a prcviou5 Iruslee of BPNAI. Dr L Hartl¢y slepped down as Iruslee on 16 January 2023. ULTIMATE CONTROLLING PARTY The trustees Consider there not io be one ultimate controlling party of the British Paediatric Neiirology Agsocialion in the current or prior year. P&ge 60